

DEX-0209

F6



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 38/00, 48/00, C07H 21/04, C12N 15/63	A1	(11) International Publication Number: WO 00/27416 (43) International Publication Date: 18 May 2000 (18.05.00)
(21) International Application Number: PCT/US99/26647 (22) International Filing Date: 10 November 1999 (10.11.99) (30) Priority Data: 09/190,976 12 November 1998 (12.11.98) US (71) Applicant: BETH ISRAEL DEACONESS MEDICAL CENTER [US/US]; 330 Brookline Avenue, Boston, MA 02215 (US). (72) Inventors: SIMONS, Michael; 115 Grove Street, Chestnut Hill, MA 02167 (US). HOROWITZ, Arie; 4503 Stearns Hill Road, Waltham, MA 02154 (US). (74) Agent: PRASHKER, David; David Prashker, p.c., 8 Chateau Heights, Magnolia, MA 01930 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: STIMULATION OF ANGIOGENESIS VIA SYNDECAN-4 CYTOPLASMIC DOMAIN SIGNALING PATHWAY (57) Abstract <p>The present invention provides a methodology and compositions for stimulating angiogenesis in-situ within viable cells, tissues and organs comprising endothelial cells. The methodology focuses upon and controls the phosphorylation of the 183rd amino acid residue, serine within the cytoplasmic domain and intracellular tail of transmembrane syndecan-4 proteoglycans which are then positioned at and through the cellular membrane of viable endothelial cells. By intervening and maintaining the 183rd residue in a non-phosphorylated state, a consequential cascade of intracellular events is initiated which result in a stimulation of angiogenesis in-situ.</p>		

24

DEX-050

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

STIMULATION OF ANGIOGENESIS VIA SYNDECAN-4
CYTOPLASMIC DOMAIN SIGNALING PATHWAY

5

RESEARCH SUPPORT

The research effort for the invention was supported by grants from National
10 Institutes of Health Grant HL-53793; the National Institutes of Health Training
Grant HL-07374; and American Heart Association Scientist Development Grant
9730282N.

15

PROVISIONAL PATENT APPLICATION

The subject matter as a whole comprising the present invention was first
filed with the U.S. Patent and Trademark Office as Provisional Patent Application
No. 60/073,711 on February 5, 1998.

20

FIELD OF THE INVENTION

The present invention is concerned generally with the stimulation of
25 angiogenesis in living tissues and organs; and is particularly directed to the
regulation of syndecan-4 cytoplasmic domain phosphorylation within endothelial
cells in-situ.

BACKGROUND OF THE INVENTION

Angiogenesis, by definition, is the formation of new capillaries and blood vessels within living tissues; and is a complex process first recognized in studies of wound healing and then within investigations of experimental tumors.

Angiogenesis is thus a dynamic process which involves extracellular matrix remodeling, endothelial cell migration and proliferation, and functional maturation of endothelial cells into mature blood vessels [Brier, G. and K. Alitalo, Trends Cell Biology 6: 454-456 (1996)]. Clearly, in normal living subjects, the process of angiogenesis is a normal host response to injury; and as such, is an integral part of the host body's homeostatic mechanisms.

It will be noted and appreciated, however, that whereas angiogenesis represents an important component part of tissue response to ischemia, or tissue wounding, or tumor-initiated neovascularization, relatively little new blood vessel formation or growth takes place in most living tissues and organs in mature adults (such as the myocardium of the living heart) [Folkman, J. and Y. Shing, J. Biol. Chem. 267: 10931-10934 (1992); Folkman, J., Nat. Med. 1: 27-31 (1995); Ware, J.A. and M. Simons, Nature Med. 3: 158-164 (1997)]. Moreover, although regulation of an angiogenetic response in-vivo is a critical part of normal and pathological homeostasis, little is presently known about the control mechanisms for this process.

A number of different growth factors and growth factor receptors have been found to be involved in the process of stimulation and maintenance of angiogenetic responses. In addition, a number of extracellular matrix components and cell membrane-associated proteins are thought to be involved in the control mechanisms of angiogenesis. Such proteins include SPARC [Sage et al., J. Cell Biol. 109: 341-356 (1989); Motamed, K. and E.H. Sage, Kidney Int. 51: 1383-1387 (1997)]; thrombospondin 1 and 2 respectively [Folkman, J., Nat. Med. 1: 27-31 (1995); Kyriakides et al., J. Cell Biol. 140: 419-430 (1998)]; and integrins $\alpha v \beta 5$ and $\alpha v \beta 3$ [Brooks et al., Science 264: 569-571 (1994); Friedlander et al., Science 270: 1500-1502 (1995)]. However, it is now recognized that a major role is played by heparan-binding growth factors such as basic fibrocyte growth factor (bFGF) and

- 3 -

vascular endothelial growth factor (VEGF); and thus the regulation of angiogenesis involves the extracellular heparan sulfate matrix and the core proteins at the surface of endothelial cells.

While growth factor signalling generally occurs through specific high-affinity receptors, several growth factors are now known to interact with adjacent, membrane-anchored, proteoglycan co-receptors. In particular, bFGF requires binding to a specific sequence of sulfated polysaccharides in the extracellular heparan sulfate glycosaminoglycan (GAG) chain [Turnbull *et al.*, J. Biol. Chem. 267: 10337-10341 (1992)] in order to bind to its high-affinity receptor on the cell surface and to exert its effect on the target cells [Olwin, B.B., and A. Rapraeger, J. Cell Biol. 118: 631-639 (1992); Rapraeger *et al.*, Science 252: 1705-1708 (1991)]. The current picture of the role of heparan sulfate in the binding mechanism of bFGF involves dimerization of the growth factor as well as direct heparan sulfate binding to the high-affinity receptor [Brickman *et al.*, J. Biol. Chem. 270: 24941-24948 (1995); Kan *et al.*, Science 259: 1918-1921 (1993)]. Together, these events lead to receptor multimerization and to tyrosine trans-phosphorylation of adjacent FGF receptor cytoplasmic tails, followed by phosphorylation of other downstream substrates [Krufka *et al.*, Biochemistry 35: 11131-11141 (1996); van der Geer *et al.*, Annu. Rev. Cell Biol. 10: 251-337 (1994)].

Research investigations have shown that heparan sulfate core proteins or proteoglycans mediate both heparin-binding growth factors and receptor interaction at the cell surface; and that accumulation and storage of such growth factors within the extracellular matrix proper typically occurs [Vlodavsky *et al.*, Clin. Exp. Metastasis 10: 65 (1992); Olwin, B.B. and A. Rapraeger, J. Cell Biol. 118: 631-639 (1992); Rapraeger, A.C., Curr. Opin. Cell Biol. 5: 844-853 (1993)]. The presence of heparin or heparan sulfate is thus required for bFGF-dependent activation of cell growth *in-vitro* [Yayon *et al.*, Cell 64: 841-848 (1991); Rapraeger *et al.*, Science 252: 1705-1708 (1991)]; and the removal of heparan sulfate chains from the cell surface and extracellular matrix by enzymatic digestion greatly impairs bFGF activity and inhibits neovascularization *in-vivo* [Sasisekharan *et al.*, Proc. Natl. Acad. Sci. USA 91: 1524-1528 (1994)]. Ample scientific

- 4 -

evidence now exists which demonstrates that any meaningful alteration of heparan sulfate (HS) chain composition on the cell surface or within the extracellular matrix (which can be initiated by means of an altered synthesis, or a degradation, or a substantive modification of glycosaminoglycan chains) can meaningfully affect the intracellular signaling cascade initiated by the growth factor. The importance of heparan sulfate in growth factor-dependent signaling has become well recognized in this field.

Heparan sulfate (HS) chains on the cell surface and within the extracellular matrix are present via a binding to a specific category of proteins commonly referred to as "proteoglycans". This category is constituted of several classes of core proteins, each of which serve as acceptors for a different type of glycosaminoglycan (GAG) chains. The GAGs are linear co-polymers of N-acetyl-D-glycosamine [binding heparan sulfate] or N-acetyl-D-galactosamine [binding chondroitin sulfate (CS) chains] and acidic sugars which are attached to these core proteins via a linking tetrasaccharide moiety.

Three major classes of HS-carrying core proteins are present in living endothelial cells: cell membrane-spanning syndecans, GPI-linked glypicans, and a secreted perlecan core protein [Rosenberg *et al.*, *J. Clin. Invest.* 99: 2062-2070 (1997)]. While the perlecan and glypican classes carry and bear HS chains almost exclusively, the syndecan core proteins are capable of carrying both HS and CS chains extracellularly. The appearance of specific glycosaminoglycan chains (such as HS and/or CS) extracellularly on protein cores is regulated both by the structure of the particular core protein as well as via the function of the Golgi apparatus intracellularly in a cell-type specific manner [Shworak *et al.*, *J. Biol. Chem.* 269: 21204-21214 (1994)].

Today, it is recognized that the syndecan class is composed of four closely related family proteins (syndecan-1, -2, -3 and -4 respectively) coded for by four different genes in-vivo. Syndecans-1 and -4 are the most widely studied members of this class and show expression in a variety of different cell types including epithelial, endothelial, and vascular smooth muscle cells, although expression in quiescent tissues is at a fairly low level [Bernfield *et al.*, *Annu. Rev. Cell Biol.* 8: 365-393 (1992); Kim *et al.*, *Mol. Biol. Cell* 5: 797-805 (1994)]. Syndecan-2 (also

- 5 -

known as fibroglycan) is expressed at high levels in cultured lung and skin fibroblasts, although immunocytochemically this core protein is barely detectable in most adult tissues. However, syndecan-3 (also known as N-syndecan) demonstrates a much more limited pattern of expression, being largely restricted to peripheral nerves and central nervous system tissues (although high levels of expression are shown in the neonatal heart) [Carey *et al.*, *J. Cell Biol.* **117**: 191-201 (1992)]. All four members of the syndecan class are capable of carrying both HS and CS chains extracellularly, although most of syndecan-associated biological effects (including regulation of blood coagulation, cell adhesion, and signal transduction) are largely thought to be due to the presence of HS chains capable of binding growth factors, or cell adhesion receptors and other biologically active molecules [Rosenberg *et al.*, *J. Clin. Invest.* **99**: 2062-2070 (1997)].

Syndecan-1 expression has been also observed during development suggesting a potential role in the epithelial organization of the embryonic ectoderm and in differential axial patterning of the embryonic mesoderm, as well as in cell differentiation [Sutherland *et al.*, *Development* **113**: 339-351 (1991); Trautman *et al.*, *Development* **111**: 213-220 (1991)]. Also, mesenchymal cell growth during tooth organogenesis is associated with transient induction of syndecan-1 gene expression [Vainio *et al.*, *Dev. Biol.* **147**: 322-333 (1991)]. Furthermore, in adult living tissues, expression of syndecan-1 and syndecan-4 proteoglycans substantially increases within arterial smooth muscle cells after balloon catheter injury [Nikkari *et al.*, *Am. J. Pathol.* **144**: 1348-1356 (1994)]; in healing skin wounds [Gallo *et al.*, *Proc. Natl. Acad. Sci. USA* **91**: 11035-11039 (1994)]; and in the heart following myocardial infarction [Li *et al.*, *Circ. Res.* **81**: 785-796 (1997)]. In the latter instances, the presence of blood-derived macrophages appears necessary for the induction of syndecan-1 and -4 gene expression.

Presently, however, the effects of changes in syndecan expression on cell behavior are not well understood. For example, this core protein is believed to mediate bFGF binding and cell activity. Overexpression of syndecan-1 in 3T3 cells led to inhibition of bFGF-induced growth [Mali *et al.*, *J. Biol. Chem.* **268**: 24215-24222 (1993)]; while in 293T cells, overexpression of syndecan-1 augmented serum-dependent growth [Numa *et al.*, *Cancer Res.* **55**: 4676-4680

- 6 -

(1995)]. Furthermore, syndecan-1 overexpression showed increased inter-cellular adhesion in lymphoid cells [Lebakken *et al.*, *J. Cell Biol.* 132: 1209-1221 (1996)] while also decreasing the ability of B-lymphocytes to invade collagen gels [Libersbach, B.F. and R.D. Sanderson, *J. Biol. Chem.* 269: 20013-20019 (1994)].

5 These ostensibly contradictory findings have merely added to the uncertainty and the disparity of knowledge regarding the effects of syndecan expression.

In addition, although there are significant differences between the sequences of their ectoplasmic domains, the four syndecans share a highly conserved cytoplasmic tail containing four invariant tyrosines and one invariant serine

10 [Kojima *et al.*, *J. Biol. Chem.* 267: 4870-4877 (1992)]. This degree of conservation may reflect functional similarities between cytoplasmic tails of all the syndecans. However, unlike the well established involvement of the ectoplasmic domain in growth factor binding through the GAG chains, there is still no consensus regarding the function of the cytoplasmic tail. Several reports [Carey *et al.*, *J. Cell Biol.* 124: 161-170 (1994); Carey *et al.*, *Exp. Cell Res.* 214: 12-21 (1994)] point to transient association of the cytoplasmic tail of syndecan-1 to the

15 actin cytoskeleton which seems to be highly dependent on the presence of one of the four conserved tyrosines [Carey *et al.*, *J. Biol. Chem.* 271: 15253-15260 (1996)].

20 It is recognized also that the 18-amino acid-long cytoplasmic tail of syndecan-4 is the least homologous to the other three syndecans, containing a unique nine-residue sequence (RMKKKDEGSYDLGKKPIYKKAPTNEFYA). Syndecan-4 is incorporated into focal adhesions of fibroblasts in a PKC-dependent manner [Baciu, P.C. and P.F. Goetinck, *Mol. Biol. Cell* 6: 1503-1513 (1995)];

25 and its cytoplasmic tail appears to bind and activate PKC α [Oh *et al.*, *J. Biol. Chem.* 272: 8133-8136 (1997)]. These capacities are special to the cytoplasmic tail of syndecan-4 and not shared by the other syndecans, because they are mediated through oligomerization of its unique nine-residue sequence [Oh *et al.*, *J. Biol. Chem.* 272: 11805-11811 (1997)].

30 Also, the presence of the five conserved phosphorylatable residues in the cytoplasmic tails of all the syndecans has been noted. However, although in-vitro phosphorylation by calcium-dependent PKC of serine residues in partial or

- 7 -

complete synthetic cytoplasmic tails was reported for syndecan-2 and syndecan-3, it could not be produced for syndecan-1 or syndecan-4 [Prasthofer *et al.*, Biochem. Mol. Biol. Int. **36**: 793-802 (1995); Oh *et al.*, Arch. Biochem. Bio Phys. **344**: 67-74 (1997)]. Serine phosphorylation in situ was detected in syndecan-2 of carcinoma cells cultured in the presence of serum [Itano *et al.*, Biochem. J. **325**: 925-930 (1996)]. This phosphorylation was attributed to the serine residue in the cytoplasmic tail of syndecan-2, contained within a sequence that conforms to a phosphorylation motif of cAMP and cGMP-dependent kinases. In situ phosphorylation of the cytoplasmic tail of syndecan-1 was produced in mammary gland cells by treatment with orthovanadate or pervanadate, both of which inhibit tyrosine phosphatase [Reiland *et al.*, Biochem. J. **319**: 39-47 (1996)]. Accordingly, this treatment resulted predominantly in tyrosine phosphorylation, although a lesser degree of serine phosphorylation was also detected. One of the four tyrosines in the cytoplasmic tail of syndecan-1 is contained within a tyrosine kinase phosphorylation motif [Gould *et al.*, Proc. Natl. Acad. Sci. USA **89**: 3271-3275 (1992)] conserved in all the syndecans and may at least partially account for the orthovanadate and pervanadate-produced phosphorylation.

In sum therefore, it is evident that the quantity and quality of knowledge presently available regarding glycosaminoglycan (GAG) binding core proteins is factually incomplete, often presumptive, and in some instance apparently contradictory. Clearly the role of specific proteoglycans, and particularly syndecans, as mediators under various conditions is recognized; nevertheless, the mechanisms of action and the functional activity of the various individual syndecan core proteins remains yet to be elucidated. Thus, while the role of proteoglycans generally is known to relate in some manner to angiogenesis, there is no evidence or data as yet which establishes the true functional action of specific proteoglycans nor which provides a means for using specific proteoglycans to stimulate angiogenesis in-situ.

SUMMARY OF THE INVENTION

The present invention is comprised of related alternatives and has multiple aspects. One aspect provides a first method for stimulating angiogenesis within various tissues and organs in-situ, said method comprising:

identifying a viable endothelial cell in-situ as a target, said targeted endothelial cell bearing a plurality of transmembrane syndecan-4 proteoglycans positioned at and through the cell surface wherein the 183rd amino acid residue present within the intracellular cytoplasmic domain of said syndecan-4 proteoglycan is a serine residue;

administering to said targeted endothelial cell on at least one occasion a predetermined amount of an inhibitor of Protein Kinase C δ (delta) isoenzyme activity such that said 183rd serine residue within the cytoplasmic domain of at least some of said syndecan-4 proteoglycans is present in a non-phosphorylated state; and

allowing said 183rd serine residue within the cytoplasmic domain of said syndecan-4 proteoglycans to continue to be present in a non-phosphorylated state, whereby a stimulation of angiogenesis in-situ results.

Another aspect provides a related, but alternative method for stimulating angiogenesis within viable cells, tissues, and organs in-situ, said alternative method comprising:

identifying a viable endothelial cell in-situ as a target, said targeted endothelial cell bearing a plurality of transmembrane syndecan-4 proteoglycans positioned at and through the cell surface wherein the 183rd amino acid residue present within the intracellular cytoplasmic domain of said syndecan-4 proteoglycan is a serine residue;

administering to said targeted endothelial cell on at least one occasion a predetermined amount of a composition able to increase Protein Kinase C α (alpha) isoenzyme activity intracellularly such that said 183rd serine residue within the cytoplasmic domain of at least some of said syndecan-4 proteoglycans is present in an non-phosphorylated state in-situ; and

- 9 -

allowing said 183rd serine residue within the cytoplasmic domain of said syndecan-4 proteoglycans to continue to be present in a non-phosphorylated state, whereby a stimulation of angiogenesis in-situ results.

5 A different aspects provides another related, but alternative method for stimulating angiogenesis within viable cells, tissues, and organs in-situ, said alternative method comprising:

identifying a viable endothelial cell in-situ as a target, said targeted endothelial cell bearing a plurality of transmembrane syndecan-4 proteoglycans positioned at and through the cell surface wherein the 183rd amino acid residue present within the intracellular cytoplasmic domain of said syndecan-4 proteoglycan is a serine residue;

administering to said targeted endothelial cell on at least one occasion a predetermined amount of an substance able to activate at least one enzyme selected from the group consisting of protein phosphatases 1 and 2A such that said 183rd serine residue within the cytoplasmic domain of at least some of said syndecan-4 proteoglycans is present in an non-phosphorylated state; and

allowing said 183rd serine residue within the cytoplasmic domain of said syndecan-4 proteoglycans to continue to be present in a non-phosphorylated state, whereby a stimulation of angiogenesis in-situ results.

BRIEF DESCRIPTION OF THE FIGURES

25 The present invention may be more easily understood and better appreciated when taken in conjunction with the accompanying drawing, in which:

Figs. 1A and 1B are photographs showing the detection of syndecan-4 core protein basal phosphorylation and identification of serine phosphorylation;

Figs. 2A and 2B are photographs showing the localization of syndecan-4 core protein phosphorylation to the cytoplasmic tail;

Figs. 3A and 3B are graphs showing the effects of bFGF and calyculin on syndecan-4 cytoplasmic tail phosphorylation;

- 10 -

Figs. 4A and 4B are photographs and a graph showing the effects of PKC activation and inhibition on syndecan-4 cytoplasmic tail phosphorylation;

Fig. 5 is a graph with insert showing the activation of PKC α (alpha) isoenzyme by syndecan-4 cytoplasmic tail peptides;

5 Figs. 6A-6C are photographs showing PKC binding to syndecan-4 cytoplasmic tail peptides;

Figs. 7A and 7B are photographs and a graph showing the binding between PIP_2 and syndecan-4 cytoplasmic tail peptides;

10 Figs. 8A-8D are graphs showing the results of size-exclusion column chromatography of syndecan-4 cytoplasmic tail peptides.

DETAILED DESCRIPTION OF THE INVENTION

15 The present invention provides both tangible means and methods for causing the 183rd residue, serine, in the cytoplasmic domain of syndecan-4 core proteins of vascular endothelial cells to exist in a non-phosphorylated state in-situ; and by this intervention and meaningful change, consequentially to effect a stimulation of angiogenesis at the local anatomic site in-vivo.

20 A number of major benefits and advantages are therefore provided by the means and methods comprising the present invention. These include the following:

1. The present invention provides in-situ stimulation for angiogenesis. By definition, therefore, both in-vivo and in-vitro circumstances of use and application are envisioned and expected. Moreover, the vascular endothelial cells which are
25 suitable for treatment using the present methods may alternatively include and be isolated endothelial cells, part of living tissues comprising a variety of other cells such as fibroblasts and muscle cells, and also comprise part of specific organs in the body of a living human or animal subject. While the user shall choose the specific conditions and circumstances for practicing the present invention, the
30 intended scope of application and the envisioned utility of the means and methods described herein apply broadly to living cells, living tissues, functional organs and systems, as well as the complete living body unit as a viable whole.

- 11 -

2. The present invention has a variety of different applications and uses. Of clinical and medical interest and value, the present invention provides the opportunity to stimulate angiogenesis in tissues and organs in a living subject which has suffered defects or has undergone anoxia or infarction. A common clinical instance is the myocardial infarction or chronic myocardial ischemia of heart tissue in various zones or areas of a living human subject. The present invention thus provides opportunity and means for specific site stimulation and inducement of angiogenesis under controlled conditions. The present invention also has major research value for research investigators in furthering the quality and quantity of knowledge regarding the mechanisms controlling angiogenesis under a variety of different conditions and circumstances.

3. The present invention envisions and permits a diverse range of routes of administration and delivery means for introducing a variety of synthetically constructed oligonucleotide expression vectors to a specific location, site, tissue, organ, or system in the living body. A variety of different vectors are available to the practitioner; and a diverse and useful range of delivery systems which are conventionally available and in accordance with good medical practice are adapted directly for use. In this manner, not only are the means for stimulating angiogenesis under the control of the user, but also the manner of application and the means for limiting the locale or area of affected vascular endothelial cells can be chosen and controlled.

4. The present invention provides a unique capability and control for stimulating angiogenesis in-situ by genetic manipulation of the endothelial cells as they exist within the tissues and organs as found. This level of control and utilization of the mechanisms found within the cytoplasm of the endothelial cells themselves provides a point of intentional intervention which harnesses and utilizes the cellular systems of the endothelial cells themselves to produce the intended and desired result. The affected endothelial cells in-situ are thus minimally altered; and the methodology utilizes the natural regulatory and protein producing systems of the endothelial cells themselves to provide the desired effect upon syndecan-4 proteoglycans which are located and positioned normally by the endothelial cells as part of the normal homeostatic mechanisms.

I. Underlying Basis Of The Invention

Recent research investigations have shown that a member of the syndecan family of heparan sulfate-carrying proteoglycans participates in intracellular signalling via its cytoplasmic tail. This particular transmembrane proteoglycan, syndecan-4, is a ubiquitous molecule present in-vivo within most human cells and tissues, including the vascular endothelium. The present invention utilizes and takes advantage of syndecan-4's cellular function in order to control and upregulate new blood vessel growth and to promote angiogenesis, particularly in the heart.

The underlying premise of the present invention is that phosphorylation of the cytoplasmic tail of syndecan-4 at the Ser¹⁸³ residue regulates a member of the protein kinase C enzyme family (PKC α), whose specific enzymatic activity is essential for proliferation and migration of endothelial cells in-vivo. As empirically demonstrated, the Ser¹⁸³-dephosphorylated residue in the syndecan-4 molecule can significantly increase the catalytic activity of PKC α , while the phosphorylated Ser¹⁸³ residue form of syndecan-4 merely activates PKC α . This result and effect is empirically proven by the experiments and data presented hereinafter. Thus, by inhibiting the Protein Kinase C isoenzyme responsible for Ser¹⁸³ phosphorylation, and/or by activating the corresponding phosphatase that removes the phosphate group from the Ser¹⁸³ residue, the means now exist to increase PKC α activity, and to promote endothelial cell proliferation and migration in-situ.

Several lines of evidence further reveal the relation between the phosphorylation level of the syndecan-4 cytoplasmic domain and its associated effects on PKC α , and the consequential proliferation and migration activities of endothelial cells. First and foremost, a significant decrease in syndecan-4 phosphorylation is observed upon cell treatment with bFGF. Thus, the occurrence of syndecan-4 dephosphorylation in the cytoplasmic tail region accompanies the proliferative response of the endothelial cells to one of the most ubiquitous growth factors, and one which is secreted in response to clinical ischemia and infarction. Second, it has only recently been observed that dephosphorylation of the cytoplasmic tail of syndecan-4 is required for its activation of PKC α . Thus,

- 13 -

syndecan-4 phosphorylation is an event directly linked to a PKC isoenzyme which is known to promote endothelial cells migration. Third, empirical data indicate that endothelial cells, in which PKC α has been suppressed by transfection with an inactive form of this enzyme kinase, proliferate at a much slower rate than wild type cells which have not been suppressed. Fourth, and finally, endothelial cells transfected with a syndecan-4 mutant bearing a Ser¹⁸³-Glu¹⁸³ replacement (which mimics the conferral of a negative charge by phosphorylation) also proliferated at a lower rate than wild type endothelial cells. Taken together, all these findings provide confirmation and evidentiary support for the role of syndecan-4 cytoplasmic tail phosphorylation in endothelial cell migration and proliferation. Consequently, control and regulation of syndecan-4 cytoplasmic tail phosphorylation is a potent methodology suitable and effective as therapies aimed at promoting angiogenesis.

II. The Syndecan-4 Cytoplasmic Domain

It will be recalled that the 28 amino acid-long cytoplasmic tail of syndecan-4 is the least homologous to the other three syndecans, containing a unique nine amino acid residue sequence (shown in bold type)

RMKKKDEGSYDLGKKPIYKKAPTNEFYA

Syndecan-4 is known to be incorporated into focal adhesions of fibroblasts in a PKC-dependent manner and its cytoplasmic tail in the phosphorylated state binds and activates PKC α directly. These capacities and functions are special to the cytoplasmic tail of syndecan-4; and these capacities and functions are not shared by the other syndecans, since they are mediated through oligomerization of the syndecan-4 cytoplasmic tail's unique nine-residue sequence.

The critical and essential target of the present methods, therefore, is the serine residue located in-situ as the 183rd amino acid in the syndecan-4 molecular structure and existing in proximity to the unique nine amino acid residue sequence of the 28 residue-long cytoplasmic tail. This individual serine residue is the sole

- 14 -

and exclusive site of interest; and it appears that no other individual amino acid residue and no peptide segment within the cytoplasmic domain is involved in any major degree.

Equally important, it will be recognized and appreciated that it is the state of this serine¹⁸³ residue - as being either non-phosphorylated or phosphorylated - which provides the invention with the means for and the effect of regulatory control. Thus, the larger the number of syndecan-4 core proteins whose intracellular cytoplasmic domain comprises an unphosphorylated serine¹⁸³ residue, the greater the upregulation of PKC α isoenzyme catalysis and the greater the inducement of angiogenesis in-situ. Conversely, the larger the number of syndecan-4 proteoglycans having a phosphorylated serine¹⁸³ residue as part of their intracellular cytoplasmic domains, the smaller the degree of PKC α isoenzyme catalysis and the more limited the amount of angiogenesis in-situ.

III. The Methodology Comprising The Present Invention

The goal and objective of the present invention is to prevent the phosphorylation of or to decrease the phosphorylation level of Ser¹⁸³ residue in the cytoplasmic domain or tail of syndecan-4 molecules then present and existing within vascular endothelial cells. The phosphorylation level of the Ser¹⁸³ residue is normally an outcome of a dynamic equilibrium between the catalytic activities of a pair of enzymes - of a specific protein kinase and a phosphatase that incorporate or remove, respectively, a phosphate group. These two enzymes are, therefore, the individual objects to be manipulated in a variety of modes. The categorical methods and goals of these manipulations thus are and include:

(A) Means and procedures to inhibit the protein kinase responsible for the phosphorylation of Ser¹⁸³ in the cytoplasmic tail of syndecan-4. This kinase has been identified and empirically shown to be the calcium-independent PKC δ (delta) isoenzyme.

- 15 -

(B) Means and procedures to increase PKC α (alpha) activity. The dephosphorylated cytoplasmic tail of syndecan-4 has been empirically shown to promote PKC α (alpha) activity, which directly increases the angiogenic potential of endothelial cells in-situ.

5 (C) Means and procedures to activate the phosphatase responsible for the dephosphorylation of the Ser¹⁸³ residue in-situ. Though the specific phosphatase has not been completely identified as yet, it belongs to and is part of the protein phosphatase type 1/2A family.

10 Composition Preparation And Manufacture

As a point of information also, it will be recognized and appreciated that in terms of preparing and using suitable inhibitory agents and compositions, it is important, if not essential, that the user be at least familiar with the many established procedures and conventionally known techniques for manipulating and
15 modifying nucleotides and DNA (and RNA) fragments as well as the vectors to carry them which have been reported and are today widespread in use and application. Merely exemplifying the many authoritative texts and published articles presently available in the literature regarding genes, DNA nucleotide manipulation and the expression of proteins from manipulated DNA fragments are
20 the following: Gene Probes for Bacteria (Macario and De Marcario, editors) Academic Press Inc., 1990; Genetic Analysis. Principles Scope and Objectives by John R.S. Ficham, Blackwell Science Ltd., 1994; Recombinant DNA Methodology II (Ray Wu, editor), Academic Press, 1995; Molecular Cloning. A Laboratory Manual (Maniatis, Fritsch, and Sambrook, editors), Cold Spring Harbor
25 Laboratory, 1982; PCR (Polymerase Chain Reaction), (Newton and Graham, editors), Bios Scientific Publishers, 1994; and the many references individually cited within each of these publications. All of these published texts are expressly incorporated by reference herein.

30

- 16 -

A. Inhibition of PKC δ (delta) Isoenzyme Activity**(A.1) Chemical PKC Inhibitory compounds:**

A vast array of chemical PKC inhibitors has been developed and is commercially available. Exemplifying such inhibitors is staurosporine, a substance obtained from *Streptomyces* species. Others are listed below in Table 1. However, most of these inhibitors are non-selective and equally potent against all types of PKC isoenzymes. One noted exception of the calcium-dependent PKC isoenzyme inhibitor is Gö 6976 [Martiny-Baron *et al.*, *J. Biol. Chem.* 268: 9194-9197 (1993)]. In so far as is presently known, however, there is no specific chemical inhibitor of the calcium-independent PKC isoenzymes in general, or of the PKC δ (delta) isoenzyme itself. For these reasons, a more specific inhibition of PKC δ alone is desirable and can be achieved by using one of the alternatives given below.

Table 1: Representative PKC Inhibitors

<u>Inhibitor</u>	<u>IC₅₀ (in μM)</u>
Calphostin C	0.05
Chelerythrine chloride	0.66
Gö 6976	0.008
Autoinhibitory peptide	15
Staurosporine	0.0007

- 18 -

(A.2) Overexpression of the autoinhibitory domain of PKC δ (delta) isoenzyme:

The regulatory domain of all PKC isoenzymes contains a sequence motif similar to the consensus sequence found in most PKC substrates in which the Thr or Ser residue normally phosphorylated by PKC is replaced by an Ala residue. In the inactive state of the enzyme, this motif blocks the catalytic domain and prevents enzyme interaction with its potential substrates. Induced over-expression of the pseudosubstrate domain of PKC δ will therefore reduce the activity of this isoenzyme by competing with its cellular substrates. Moreover, the pseudosubstrate domain of PKC δ is sufficiently different from those of the other PKC isoenzymes so as not to interfere with their catalytic activity. The pseudosubstrate domain of PKC δ (delta) isoenzyme is provided by Table 2 below.

It will be recognized that the information of Table 2 is a reproduction in part from Nishikawa *et al.*, *J. Biol. Chem.* 272: 952-960 (1997), the full text of which is expressly incorporated by reference herein.

Table 2: The Pseudosubstrate Domain of the PKC δ (delta) Isoenzyme

AARKRKGSFFYGG

- 20 -

Over-expression of the PKC δ pseudosubstrate can be produced within the endothelial cell at the target region by transfection with the adenovirus containing a cDNA construct with the PKC δ pseudosubstrate sequence of Table 2. An established protocol and procedural detail has been reported and published in the scientific literature by Nishikawa *et al.*, *J. Biol. Chem.* 272: 952-960 (1997); the text of this publication and its cited references is expressly incorporated by reference herein. The prepared adenovirus vector carrying the inserted DNA coding for the pseudosubstrate domain of the PKC δ (delta) isoenzyme can be administered by direct injection or infusion to the local anatomic site of the host in-vivo over a schedule dose administration over a period of days.

(A.3) Expression of PKC δ anti-sense constructs

Transfection with the anti-sense cDNA of a protein is a frequently used method for suppressing the expression of that protein. The mRNA transcribed from the transfected cDNA shuts off the translation of the target protein by hybridizing to the sense endogenous mRNA message. The delivery method of the anti-sense cDNA is similar to the one used above for over-expressing the pseudosubstrate domain of PKC δ , preferably also using the adenovirus vector for administration.

As a representative specific example of an antisense entity useful with the present invention, the PKC δ (delta) antisense sequences (I) and (II) are given below.

(I) PKC Delta antisense primer (42 mer):

5'-GGC CGC TGG GCA TCG AAC GTC GAC TTC CAC TCA GGA
TAC ATG-3'

(II) PKC Delta antisense complement primer (42 mer):

5'-GAT CCA TGT ATC CTG AGT GGA AGT CGA CGT TCG ATG
CCC AGC-3'

- 21 -

It will be recognized and appreciated that these two embodiments are merely representative and illustrative of this type of inhibitory compound; and that a wide range of other DNA oligonucleotide fragments can be prepared which will be useful and functional in varying degrees of efficacy.

5

(A.4) Delivery of anti-sense oligodeoxynucleotides (ODN)

In this approach, a short (around 15-30 base pairs) ODN with an anti-sense sequence corresponding to a chosen sequence in the cDNA of the protein intended for suppression is introduced in the target cells. The principle of this method is similar to that of the anti-sense construct, but instead of interfering with translation of the mRNA, this approach interferes with transcription by hybridization between of exogenous anti-sense ODN to the corresponding locus in the genomic DNA.

10

B. Increases in PKC α (alpha) Isoenzyme Activity

15

(B.1) Chemically Induced Increases in PKC α Activity

In addition to enhancing PKC α activity through prevention of syndecan-4 cytoplasmic tail phosphorylation, this PKC α activity can be increased directly.

The commonly used compounds for increasing PKC activity are phorbol esters, but these compositions are not isoenzyme-specific. A representative listing of useful phorbol esters and other PKC activators, all of which are commercially available, is provided by Table 3 below. In addition, however, an increase in PKC activity limited to the α (alpha) isoenzyme can be achieved using one of the alternative methods described below.

20
25

Table 3: Representative Phorbol Ester Compositions

ADMB;

Ingenol;

1,2-Didecanoyl-rac-glycerol-Mezerein;

Phorbol-12-myristate-13-acetate (PMA);

1-stearoyl-2-arachidonoyl-SN-glycerol;

12-0-tetradecanoyl-phorbol-13-acetate (TPA)

- 23 -

(B.2) Over-expression of full-length PKC α molecules

A marked increase in the number and abundance of PKC α (alpha) isoenzyme molecules will elevate the phosphorylation level of its downstream substrates, resulting in higher proliferative and migratory cellular activities. Such increase can be achieved by introducing exogenous cDNA encoding the full-length PKC α (alpha) isoenzyme using adenoviral transfection as conventionally known and practiced. For ease of understanding and completeness of description, a recitation of cDNA encoding the entirety of the PKC α (alpha) isoenzyme is provided by Table 4 below.

In addition, the cDNA recitation of Table 4 will be recognized as a reproduction in-part of the scientific information published in Parker et al., Science 233: 853-859 (1986), the full text of which is expressly incorporated by reference herein.

15

- 24 -

Table 4: cDNA Encoding the PKC α (alpha) Isoenzyme

LOCUS BOVPKIC 2324 bp mRNA MAM 08-APR-1987
 DEFINITION Bovine protein kinase C mRNA, complete cds.
 ACCESSION M13973
 NID g163529
 KEYWORDS kinase; phorbol ester receptor; protein kinase; protein kinase C;
 serine kinase; threonine kinase.
 SOURCE Bovine (calf) brain, cDNA to mRNA, clones lambda-bPKC[21,306].
 ORGANISM Bos taurus
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Artiodactyla; Ruminantia; Pecora; Bovoidea;
 Bovidae; Bovinae; Bos.
 REFERENCE 1 (bases 1 to 2324)
 AUTHORS Parker, P.J., Coussens, L., Totty, N.F., Rhee, L., Young, S., Chen, E.,
 Stabel, S., Waterfield, M.D. and Ullrich, A.
 TITLE The complete primary structure of protein kinase C-the major
 phorbol ester receptor
 JOURNAL Science 233, 853-859 (1986)
 MEDLINE 56289425
 FEATURES Location/Qualifiers
 source 1..2324
 /organism="Bos taurus"
 /db_xref="taxon:9913"
 mRNA <1..>2324
 /note="pkC mRNA"
 CDS 51..2069
 /note="protein kinase C"
 /codon_start=1
 /db_xref="PID:g163530"
 /translation="MADVFPAAEPAAPQDVANRFARKGALRQKNVHEVKNHRFIARFF
 KQPTFCSHCTDFIWGFGKQGFQCCFVVHKRCHEFVTFSCPGADKGPDTDDPRSKH
 KFKIHTYGSPTFCDCGSLLYGLIHQGMKCDTCDMNVHKQCVINVPSCGMDHTEKRG
 RIYLKAEVTDEKLHVTVRDAKNLIPMDPNGLSDPYVKLKLIPDPKNEKQKTKTIRST
 LNPRWDESFTEFLKPSDKDRRLSEEIWDWDRTRNDFMGSLSGVSGVSELMKMPASGWYK
 LLNQEEGEYTNVPIFEGDEEGNVLLRQKFEKAKLGFAGNKVISPSEDRRQPSNNLDRV
 KLTDFNFLMVLGKGSFGKVMLADRKGTEELYAIKILKKDQVVIQDDDVECTMVEKRVLA
 LLDKPPFLTOLHSCFQTVDRLYFVMEYVNGGDLMYHIQQVGKFKPEOAVFYAAEISIG
 LFFLHKRGIIRDLKLDNVMLDSEGHIKIADFGMCKEHHMDGVVTRTFCGTDPDYIAPE
 TIAYQPIGRSVDDWYAGVLLYEMLAGQPPFDGEDELEFQSIMHNVSYPKSLSKEAV
 SICKGLMTKHPGKRLGCGPEGERDVREHAFFRRLDWEKLENREIQPPFKPKVCCKGAE
 NFDKFFTRGQPVLTTPDQLVIANIDQSDFEFGFSYVNPQFVHPILQSAV"
 catalytic domain
 (underlined)
 BASE COUNT 527 a 683 c 695 g 419 t
 ORIGIN 201 bp upstream of PstI site.
 1 ccctctcggc cgccgcccgc gccccccgcg gcaggaggcg gcgagggacc atggctgacg
 61 tcttcccggc cgccgagccg gcggcgccgc aggacgtggc caaccgcttc gcccgcaaa
 121 gggcgctgag gcagaagaac gtgcacgagg tgaagaacca ccgcttcacg gcgcgcttct
 181 tcaagcagcc caccttctgc agccactgca ccgacttcat ctgggggttt gggaaacaag
 241 gcttccagtg ccaagtttgc tgttttgtgg ttcacaagag gtgccatgaa tttgttactt
 301 tttcttgtcc gggggcgcat aaaggacccg acacagatga cccgaggagc aagcacaagt
 361 tcaagatcca cacgatggc agccccacct tctgtgatca ctgcggctcc ctgctctacg
 421 gactcatcca ccaggggatg aaatgtgaca cctgtgatat gaacgtgcac aagcagtgcg
 481 tgatcaacgt gcccgagcctc tgcgggatgg accacacgga gaagaggggc cgcattctacc
 541 tgaaggccga ggtcacggat gaaaagctgc acgtcacagt acgagacggc aaaaacctaa
 601 tccctatgga tccaaatggg ctttcagatc cttacgtgaa gctgaagctt attcctgacc
 661 ccaagaacga gagcaaacag aaaaccaaga ccatccgctc gacgctgaac ccccggtggg
 721 acgagtcctt cacgttcaaa ttaaaacctt ctgataaaga ccggcgactg tccgaggaaa
 781 tctgggactg ggatcgaacc acacggaacg acttcatggg gtccctttcc tttggggtct
 841 cggagctgat gaagatgccg gccagcggat ggtacaagct gctgaaccaa gaggaggcgc
 901 agtactacaa cgtgccgatc cccgaaggcg acgaggaagg caatgtggag ctgaggcaga

Table 4: cDNA Encoding the PKC α (alpha) Isoenzyme (continued)

```

961 aattcgagaa agccaagctt ggcctgccc gcaacaaagt catcagtcct tccgaggaca
1021 ggagacagcc ttccaacaac ctggacagag tgaagctcac ggacttcaac ttcctcatgg
1081 tgctgggcaa aggcagcttt gggaaggtag tgctggccga ccggaagggg acagaggagc
1141 tgtacgcat caagatcctg aagaaggacg tggatcatca ggacgacgac gtggagtgcg
1201 ccatggtgga gaagcgggtc ctggcgctgc tcgacaagcc gccgttctct acgcagctgc
1261 actcctgctt ccagacgggtg gaccggctgt acttcgtcat ggagtacgtc aacggcgggg
1321 acctcatgta ccacatccag caggctcgga agttcaagga gccgcaagca gtgttctatg
1381 cagcagagat ttccatcggg ctgttctttc ttcataaaag aggaatcatt tatcgggacc
1441 tgaagttaga caacgtcatg ctggactcgg aaggacacat taagatcgcg gacttcggga
1501 tgtgcaagga gcacatgatg gacggcgctc cgaccaggac cttctgcggg acccccgact
1561 acatcgcccc agagataatc gcctatcagc cgtacgggaa gtccgtggac tgggtggcct
1621 acggcgctcct gttgtacgag atgttgccg ggacgctcc gtccgacggc gaggacgagg
1681 acgagctgtt ccagtcctac atggagcaca acgtctcgta cccaagtcct ttgtccaagg
1741 aggcctgtgc catctgcaaa ggcctgatga ccaagcacc cgggaagcgg ctgggctgcg
1801 ggcgcgaggg cgagcgcgac gtgcgggagc atgccttctt ccggaggatc gactgggaga
1861 agctggagaa ccgtgagatc cagccaccct tcaagcccaa agtgtgcggc aaaggagcag
1921 agaactttga caagttcttc acgcgagggc agcctgtctt gacgcgccc gaccagctgg
1981 tcatcgctaa catcgaccag tctgattttg aaggtctctc ctacgtcaac cccagttcg
2041 tgcaccccat cctgcagagc gcggtatgag acgcctcgcg gaagcctggt ccgcgcccc
2101 gcccccgctt ccgccccgcg cgtgggaagc gacccccacc ctagggtttg ccggcctcgg
2161 ccctccctgt tccaggtgga ggcctgaaaa ctgtagggtg gttgtccccg cgtgctcggc
2221 tgcgtcatct cagcgggaaga tgacgtcacg tcggcatctg cttgacgtag aggtgacatc
2281 tggcggggga ttgacccttt ctggaagaca aacagactct ggcc

```

(B.3) Over-expression of PKC α catalytic domain

A larger increase in PKC α activity can be achieved by over-expressing only the cDNA encoding its unregulated catalytic subunit (PKM), instead of the full-length protein. The catalytic subunit (PKM) is constitutively active in and of itself; and will increase the basal activity of PKC α when introduced to a viable cell even in the absence of external activation. A recitation of the cDNA encoding the catalytic subunit (PKM) alone of the PKC α (alpha) isoenzyme is provided by Table 5 below. It will be appreciated that the recitation of Table 5 is a reproduction in part of the information presented by Parker et al., Science 233: 853-859 (1986), the full text of which is expressly incorporated by reference herein.

Table 5: cDNA Encoding the Catalytic Subunit (PKM) of
PKC α (alpha) Isoenzyme

```
acggacttca acttcctcat ggtgctgggc aaaggcagct ttgggaaggt gatgctggcc
gaccggaagg ggacagagga gctgtacgcc attaatatcc tgaagaagga cgtggtcac
caggacgacg acgtggagtg caccatggtg gagaagcggg tcctggcgct gctcgacaag
ccgccgttcc tgacgcagct gcactcctgc ttccagacgg tggaccggt gtacttcgtc
atggagtacg tcaacggcgg ggacctcatg taccacatcc agcaggtcgg gaagttcaag
gagccgcaag cagtgttcta tgcagcagag atttccatcg ggctgttctt tcttcataaa
agaggaatca tttatcggga cctgaagtta gacaacgtca tgctggactc ggaaggacac
attaagatcg cggacttcgg gatgtgcaag gagcacatga tggacggcgt caccaccagg
accttctgcg ggacccccga ctacatcgcc ccagagataa tcgcctatca gccgtacggg
aagtccgtgg actggtgggc ctacggcgtc ctgttgtagc agatgttggc cgggcagcct
ccgttcgacg gcgaggacga ggacgagctg ttccagtcca tcatggagca caacgtctcg
taccccaagt ccttggtccaa ggaggccgtg tccatctgca aagggtgat gaccaagcac
cccggaagc ggctgggctg cgggcccgag ggcgagcgcg acgtgcggga gcatgccttc
ttccggagga tc
```

C. Activation of protein phosphatase 1/2A

As noted previously herein, the field of phosphatases responsible for dephosphorylating the Ser¹⁸³ in the cytoplasmic tail of syndecan-4 in-situ has been
5 narrowed markedly to protein phosphatase type 1 (PP1) or 2A (PP2A). This fact has been experimentally verified hereinafter.

In addition, the capacity of okadaic acid to inhibit the dephosphorylation of the cytoplasmic tail of syndecan-4 is being employed to discriminate between the two enzyme types. Since protein phosphatase PP2A is more sensitive to okadaic
10 acid than type PP1 enzyme, these experiments will serve to discriminate between the two enzyme types. After the phosphatase type is determined and precisely identified, the following procedures can be used to increase phosphatase enzyme activity in the target cell population:

15 (C1) Over-expression of the catalytic subunits of the protein phosphatase

Protein phosphatase type PP1 is a multimer consisting of a catalytic subunit and one of several known inhibitory subunits [Mumby, M.C. and G. Walter, Physiol. Rev. 73: 673-699 (1993)]. In comparison, protein phosphatase type PP2A
20 is a heterotrimer of two regulatory subunits (A and B) and a catalytic subunit (C). Once it has been determined whether type PP1 or type PP2A is responsible for dephosphorylating the cytoplasmic tail of syndecan-4, the respective catalytic subunit can be over-expressed by adenoviral transfection with the cDNA of this subunit. For informational purposes, the DNA sequence for both types PP1 and
25 PP2A is provided by Table 6 below.

- 29 -

Table 6

LOCUS HUMPRPHOS1 1367 bp mRNA PRI 22-APR-1991
 DEFINITION Human protein phosphatase-1 catalytic subunit mRNA, complete cds.
 ACCESSION M63960
 NID g190515
 KEYWORDS dephosphorylate phosphoprotein; protein phosphatase-1.
 SOURCE Human liver hepatoma Hep G2 cell line, cDNA to mRNA, clone
 PP1HEPG2-B.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1367)
 AUTHORS Tung, L.
 JOURNAL Unpublished (1991)
 FEATURES
 source Location/Qualifiers
 1..1367
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_line="Hep G2"
 /cell_type="hepatoma"
 /tissue_type="liver"
 /tissue_lib="Hep G2 cDNA library"
 CDS
 30..1022
 /EC_number="3.1.3.16"
 /note="catalytic subunit"
 /codon_start=1
 /product="protein phosphatase-1"
 /db_xref="PID:g190516"
 /translation="MSDSEKLNLDISIIGRLLEVQGSRPQKNVQLTENEIRGLCLKSRE
 IFLSQPIILLELEAPLKICGDIHQYYDLLRLFYGGFPPESNYLFLGDYVDRGKQSL
 TICLLLAYKIKYPENFFLLRGNHECASINRIYGFYDECKRRYNIKLWKTFTDCFNCLP
 IAAIVDEKIFCCHGGLSPDLQSMQIRIRMRPTDVPDQGLLCDLLWSDPKDQVQWGE
 NDRGVSFTFGAEVVAKFLHKHOLDLICRAHQVVEDGYEFFAKRQLVTLFSAPNYCGEF
 DNAGAMMSVDETLMSFQILKPADKNKGKYQFSGLNPGGRPITPPRNSAKAKK"
 BASE COUNT 288 a 400 c 393 g 286 t
 ORIGIN
 1 gggcaaggag ctgctggctg gacggcgga tgtccgacag cgagaagctc aacctggact
 61 cgatcatcgg ggccctgctg gaagtgcagg gctcgcggcc tggcaagaat gtacagctga
 121 cagaacaacga gatccgcggt ctgtgcctga aatcccgga gattttctg agccagccca
 181 tctttctgga gctggaggca cccctcaaga tctgcggtga catcacaggc cagtactacg
 241 accttctgag actatttgag tatggcggtt tccctccga gagcaactac ctctttctgg
 301 gggactatgt ggacaggggc aagcagtcct tggagaccat ctgcctgctg ctggcctata
 361 agatcaagta ccccgagaac ttcttctgct tccgtgggaa ccacgagtgt gccagcatca
 421 accgcatcta tggtttctac gatgagtga agagacgcta caacatcaaa ctgtggaaaa
 481 ccttcactga ctgcttcaac tgctgcccc tgcggccat agtggacgaa aagatcttct
 541 gctgccacgg aggcctgtcc ccggacctgc agtctatgga gcagattcgg cggatcatgc
 601 ggccacacaga tgtgcctgac cagggcctgc tgtgtgacct gctgtggtct gacctgaca
 661 aggacgtgca gggctggggc gagaacgacc gtggcgctct tttaccttt ggagccgagg
 721 tgggtggccaa gttcctccac aagcacgact tggacctcat ctgccgagca caccaggtgg
 781 tagaagacgg ctatgagttc ttgccaagc ggcagctggt gacacttttc tcagctccca
 841 actatgtgg cgaatttgac aatgctggcg ccattgatgag tgtggacgag acctcatgt
 901 gctttttcca gatcctcaag cccgccgaca agaacaaggg gaagtacggg cagttcagtg
 961 gcttcaaccc tggaggccga cccatcacc caccocgcaa ttccgcaaaa gccaagaaat
 1021 agcccccgcga caccacctg tgcctcagat gatggattga ttgtacagaa atcatgtctg
 1081 catgctgggg gggggtcacc ccgacctta aggccacct gtcacgggga acatggagcc
 1141 ttgggtgatt tttttttct ttttttaag aatcaatagc agcgtccagt ccccgaggc
 1201 tgccttctgc ctgcacctgc ggtactgtga gcaggatcct ggggcccagg ctgcagctca
 1261 gggcaacggc aggccaggtc gtgggtctcc agccgtgctt ggctcaggc tggcagcccc
 1321 gatcctgggg caacctatct ggtctcttga ataaaggtca aagctgg

Table 6 (continued)

LOCUS BCOVPH02A 1721 bp mRNA MAM 15-JUN-1988
 DEFINITION Bovine protein phosphatase type 2A catalytic subunit mRNA, complete cds.
 ACCESSION M16968
 NID g163515
 KEYWORDS phosphoprotein phosphatase 2A.
 SOURCE Bovine adrenal, cDNA to mRNA, clone pPBC-1.
 ORGANISM Bos taurus
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Artiodactyla; Ruminantia; Pecora; Bovoidea;
 Bovidae; Bovinae; Bos.
 REFERENCE 1 (bases 1 to 1721)
 AUTHORS Green, D.D., Yang, S.-I. and Mumby, M.C.
 TITLE Molecular cloning and sequence analysis of the catalytic subunit of bovine type 2A protein phosphatase
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 84, 4880-4884 (1987)
 MEDLINE 87260892
 COMMENT Draft entry and printed copy of sequence for [1] kindly provided by M.C.Mumby, 09-SEP-1987.
 FEATURES
 source Location/Qualifiers
 1..1721
 /organism="Bos taurus"
 /db_xref="taxon:9913"
 mRNA
 <1..1721
 /note="PP-C mRNA"
 CDS
 104..1081
 /note="protein phosphatase type 2A catalytic subunit"
 /codon_start=1
 /db_xref="PID:g163516"
 /translation="MDEKVFTEKELDOWIEQLNECKQLSESQVKS LCRRLKKS WT KESN
 VQEVRCPTVVRG DVHGQF HDLMELFRIGGKSPDTNYLFMGDYVDRGYYSVETVTL LVA
 LKVR YRERITILRG NHESRQITQVYGFYDECLRKYGNANVWKYFTDLFDYLP L TALVD
 GQIFCLHGGLSPSIDTL D HIRALDRLQEV PHEGPMCDLLWSDPDRGGWGISPRGAGY
 TFGQDISETFNHANGLTLVSR AHQLVMEGYNWCHDRNVVTIF SAPNYCYRCGNQAAIM
 ELDDTLKYSFLQFDPAPAEASHMLLVVPQTTSCEILNLYSIAMNHILT"
 BASE COUNT 477 a 349 c 398 g 497 t
 ORIGIN 13 bp upstream of SmaI site.
 1 tcacaaatac ccggaacc gggcgccgt gtgcgtgtgc ccgctgtgc ggcggcgccg
 61 cgggaggagc cgggagcggc agccggttcg gccgggtggc atcatggacg agaaggtgtt
 121 caccaggag ctggaccagt ggatcgagca gctgaacgag tgcaagcagc tgtctgagtc
 181 ccagggttaag agcctctgca gaaggctaaa gaaatcctgg acaaaaagaat ccaatgtgca
 241 aqaagtccga tgtccagtca ctgtccgtgg agatgtgcat gggcaatttc atgattccat
 301 ggaactgttt agaattggtg gcaaatacc agatacaaat tacttgttta tgggcgatta
 361 tgttgacaga ggatattatt cagtggaaac agttactctg cttgtagctc ttaagggttcg
 421 ttaccgtgaa cgtatcacca ttcttcgagg aaatcatgag agcagacaga tcacacaagt
 481 atatgggttc tacgatgagt gtttaaggaa atacggaaat gcaaatgttt ggaagtattt
 541 tacagacert ttgactatc ttctctcac tgccttgggt gatgggcaga tcttctgtct
 601 acatgggtgg cttccacccat ccatagatac actggatcac atcagagcac ttgatgcctt
 661 acaagaagtt cctcatgagg gtccaatgtg tgacttgctg tggtcagatc cagatgaccg
 721 tggagggtgg ggtatatctc ctcgaggagc tggttacacc tttgggcagg atatttctga
 781 gacatttaac catgccaatg gcctcacgtt ggtgtctaga gctcatcagc tggatgagga
 841 gggatataac tgggtccatg accgaaatgt agtaacgatt ttcatgtctc caaactattg
 901 ttatcggtgt ggtaaccaag ctgcaatcat ggaacttgat gatactctaa aatactcttt
 961 cttgcagttt gaccagcac ccgcagaggc gagccacatg ttactcgctg taccocagac
 1021 tttttctgtt aatgaaattt taaacttgta cagtattgcc atgaaccata tattgacctt
 1081 atggatatgg gaagagcaac agtaactcca caagtgtcag agaatagtta acattcaaaa
 1141 aaacttgttt tcacacggac caaaaagatg tgccatataa aaatacaaaag cctgtcatca
 1201 acagccgtga ccactttaga atgaaccagt tcattgcatg ctgaagcgac attgttggct

Table 6 (continued)

```
1261 aagaaaccag tttctggcat agcgtatatt gtagttactt tgctttctct gagagactgc
1321 agataagatg taaacattaa cacctcgtga atacaattta acttccattt agctatagct
1381 ttactcagca tgactgtagg ataagaatag cagcaaacaa tcattggagc ttaatgaaca
1441 tttttaaaaa taagraccaa ggctccccct ctacttggtga gttttaaaat cgtttttggt
1501 ttttttcagg gtaccgttta atttaattgt atgatttgtc tcgcatcagt ttattttccc
1561 tctcaaattct agcctcatgt tgttctttgt tactgtcaca acctgggtgag ttgttttgaa
1621 tggaaattgt tttttttctc cctgctgtaa gatgatgta ctgcacaaga gcactgcagt
1681 gtttttcata ataaacttgt gaactaagag atgaaaaagt c
```

(C2) Suppression of the protein phosphatase regulatory subunits

- 5 As a complementary approach to the one described in Section c.1, the expression of the regulatory subunits of either PP1 (inhibitor-1, inhibitor-2, or DARPP-32) or PP2A can be suppressed by one of the techniques described previously herein. For informational purposes, the DNA sequences of these substances is provided by Table 7 below.

Table 7

LOCUS AI139158 481 bp mRNA EST 23-SEP-1998
 DEFINITION cc19d12.x1 Soares_fetal_heart_NbHH19W Homo sapiens cDNA clone
 IMAGE:1710071 3' similar to SW:IPPI_HUMAN Q13522 PROTEIN
 PHOSPHATASE INHIBITOR 1 ;, mRNA sequence.

ACCESSION AI139158
 NID g3645130
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 481)
 AUTHORS NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.
 TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
 Tumor Gene Index
 JOURNAL Unpublished (1997)
 COMMENT Contact: Robert Strausberg, Ph.D.
 Tel: (301) 496-1550
 Email: Robert_Strausberg@nih.gov
 This clone is available royalty-free through LLNL ; contact the
 IMAGE Consortium (info@image.llnl.gov) for further information.
 Seq primer: -40m13 fwd. ET from Amersham
 High quality sequence stop: 459.

FEATURES
 source Location/Qualifiers
 1..481
 /organism="Homo sapiens"
 /note="Organ: heart; Vector: pT7T3D (Pharmacia) with a
 modified polylinker; Site 1: Not I; Site 2: Eco RI; 1st
 strand cDNA was primed with a Not I - oligo(dT) primer (5'
 TGTTACCAATCTGAAGTGGGAGCGGCCGCATCTTTT TTTT TTTT TTTT 3'),
 double-stranded cDNA was size selected, ligated to Eco RI
 adapters (Pharmacia), digested with Not I and cloned into
 the Not I and Eco RI sites of a modified pT7T3 vector
 (Pharmacia). Library went through one round of
 normalization to a Cot = 5. Library constructed by
 M.Fatima Bonaldo. This library was constructed from the
 same fetus as the fetal lung library, Soares fetal lung
 NbHL19W."
 /db_xref="taxon:9606"
 /clone="IMAGE:1710071"
 /clone_lib="Soares_fetal_heart_NbHH19W"
 /sex="unknown"
 /dev_stage="19 weeks"
 /lab_host="DH10B (ampicillin resistant)"

BASE COUNT 89 a 123 c 118 g 151 t
 ORIGIN
 1 ttgacctaac accaaattta tcacttttta aaaacaagag attttcccca aaagtgaagg
 61 aataagaaac aaatccggtg tccatgcatt cccaaactgc agtcttgatc ccaagatacc
 121 tctctctctc tcagaccgag ttggtccctc tggaaatccag tgggtggata tggggtgagg
 181 gttcttttgt gctgggtccc ttaactgcctc tctcgtgagt tttagggatg cattctgcag
 241 ttttttttgc tgtcccagag gtgcccagcc ttgactccac ttctgtgtct gggatcccag
 301 gtgggaggga ctccctgggt cctgtgctct cagcggcccc ctacaggttcc tctccttgct
 361 gctgttgccc caggtgatgt tcaaccatca tctggagctc ttccattgtg ggtgtgatcc
 421 tctgcatctc ctcccggtgc cgtggagaca ttgccaaagt ggacttgaga tgtgggttgg
 481 g

Table 7 (continued)

LOCUS AA188560 439 bp mRNA EST 10-MAR-1998
 DEFINITION zp78f05.r1 Stratagene HeLa cell s3 937216 Homo sapiens cDNA clone
 626337 5' similar to SW:IPP2_HUMAN P41236 PROTEIN PHOSPHATASE
 INHIBITOR 2 ;, mRNA sequence.
 ACCESSION AA188560
 NID q1775788
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 439)
 AUTHORS Hillier, L., Allen, M., Bowles, L., Dubuque, T., Geisel, G., Jost, S.,
 Krizman, D., Kucaba, T., Lacy, M., Le, N., Lennon, G., Marra, M.,
 Martin, J., Moore, B., Schellenberg, K., Steptoe, M., Tan, F.,
 Theising, B., White, Y., Wylie, T., Waterston, R. and Wilson, R.
 TITLE WashU-NCI human EST Project
 JOURNAL Unpublished (1997)
 COMMENT
 Contact: Wilson RK
 Washington University School of Medicine
 444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
 Tel: 314 286 1800
 Fax: 314 286 1810
 Email: est@watson.wustl.edu
 This clone is available royalty-free through LLNL ; contact the
 IMAGE Consortium (info@image.llnl.gov) for further information.
 Insert Length: 1296 Std Error: 0.00
 Seq primer: -28M13 rev2 from Amersham
 High quality sequence stop: 368.
 FEATURES
 source Location/Qualifiers
 1..439
 /organism="Homo sapiens"
 /note="Vector: pBluescript SK-; Site_1: EcoRI; Site_2:
 XhoI; Cloned unidirectionally. Primer: Oligo dT. HeLa S3
 epithelioid carcinoma cells grown to semi-confluency
 without induction. Average insert size: 1.5 kb; Uni-ZAP XR
 Vector. -5' adaptor sequence: 5' GAATTCGGCAGAG 3' -3'
 adaptor sequence: 5' CTCGAGTTTTTTTTTTTTTTTTTTT 3'"
 /db_xref="GDB:5045035"
 /db_xref="taxon:9606"
 /clone="626337"
 /clone_lib="Stratagene HeLa cell s3 937216"
 /sex="female"
 /dev_stage="HeLa S3 cell line"
 /lab_host="SOLR (kanamycin resistant)"
 BASE COUNT 154 a 89 c 112 g 83 t 1 others
 ORIGIN
 1 gacttcctct atggtggcgt cggcgaacag cccgcggga atgtcgacga ggagctgagc
 61 aaaaaatccc agaagtggga tgaaatgaac atcttgccga cgtatcatcc agcagacaaa
 121 gactatgggt taatgaaat agatgaacca agcactcctt accatagtat gatgggggat
 181 gatgaagatg cctgtagtga caccgaggcc acttgaagcc atggcgccag acatctttag
 241 ccaggaaatt agctgcagct gaaggcttgg agccaaagta tcggattcag gaacaagaaa
 301 gcagtggaga ggaggatagt gacctctcac ctgaagaacg agaaaaaaag cgacaatttg
 361 aaatgaaaag gaagcttcac tacaatgaag gactcaatat caaactagcc agacanttaa
 421 tttcaaaaaga cctacatga

Table 7 (continued)

LOCUS HSU60823 750 bp mRNA PRI 11-JUL-1996
 DEFINITION Human potent heat-stable protein phosphatase 2A inhibitor I1PP2A
 mRNA, complete cds.
 ACCESSION U60823
 NID g1408223
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 750)
 AUTHORS Li, M., Makkinje, A. and Damuni, Z.
 TITLE Molecular identification of I1PP2A, a novel potent heat-stable
 inhibitor protein of protein phosphatase 2A
 JOURNAL Biochemistry 35 (22), 6998-7002 (1996)
 MEDLINE 96240314
 REFERENCE 2 (bases 1 to 750)
 AUTHORS Li, M., Makkinje, A. and Damuni, Z.
 TITLE Direct Submission
 JOURNAL Submitted (13-JUN-1996) Cellular & Molecular Physiology,
 Pennsylvania State University College of Medicine, 500 Univeristy
 Drive, Hershey, PA 17033, USA
 FEATURES
 source Location/Qualifiers
 1..750
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /tissue_type="kidney"
 CDS 1..750
 /codon_start=1
 /product="potent heat-stable protein phosphatase 2A
 inhibitor I1PP2A"
 /db_xref="PID:g1408224"
 /translation="MEMGRRRIHLELRNRTPSDVKELVLDNSRSNEGKLEGLTDEFEEEL
 EFLSTINVGLTSIANLPKLNKLLKLELSDNRVSGGLEVLAEKCPNLTHNLSGNKIKD
 LSTIEPLKKLENLKSLLDFNCEVTNLNDYRENVFKLLPOLTYLDGYDRODKEAPSDA
 EGYVEGLDDEEEDDEEYDEDAQVVEDEEEDDEEEDVSGEEEDDEEGYNDGE
 VDDEEEDDEELGEEERGQKRKREPEDEGEDDD"
 BASE COUNT 260 a 130 c 229 g 131 t
 ORIGIN
 1 atgcagatgg gcagacggat tcatttagag ctgcggaaca ggacgccctc tgatgtgaaa
 61 gaacttgtcc tggacaacag tcggtcgaat gaaggcaaac tcgaaggcct cacagatgaa
 121 ttggaagaac tgggaattctt aagtacaatc aacgtaggcc tcacctcaat cgcaaaactta
 181 ccaaagttaa acaaaacttaa gaagcrtgaa ctaagcgata acagagtctc agggggcctg
 241 gaagratattg cagaaaaagtg tccgaacctc acgcatctaa atttaagtgg caacaaaaatt
 301 aaagacacctc gcacaataga gccactgaaa aagttagaaa acctcaagag cttagacctt
 361 ttcaattcgc aggttaaccaa cctgaacgac taccgagaaa atgtgttcaa gtcctctccg
 421 caacttcacat atctcgacgg ctatgaccgg gacgacaagg agggccctga ctcggatgct
 481 gagggctacg tggagggcct ggatgatgag gaggaggatg aggatgagga ggagtatgat
 541 gaagatgctc aggtactgga agacgaggag gacgaggatg aggaggagga aggtgaagag
 601 gaggacgtga gtggagagga gaggaggatg gaagaagggt ataacgatgg agaggtatgat
 661 gacgagggaag atgaagaaga gcttggtgaa gaagaaaggg gtcagaagcg aaaacgagaa
 721 cctgaagatg agggagaaga tgatgactaa

Table 7 (continued)

LOCUS BOVDARPP32 1691 bp mRNA MAM 15-DEC-1994
 DEFINITION Bos taurus (clone pTKD7) dopamine and cyclic AMP-regulated neuronal phosphoprotein (DARPP-32) mRNA, complete cds.
 ACCESSION M27444
 NID g602437
 KEYWORDS phosphoprotein.
 SOURCE Bos taurus calf brain (caudate nucleus) cDNA to mRNA.
 ORGANISM Bos taurus
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Artiodactyla; Ruminantia; Pecora; Bovoidea;
 Bovidae; Bovinae; Bos.
 REFERENCE 1 (bases 1 to 1691)
 AUTHORS Kurihara, T., Lewis, R.M., Eisler, J. and Greengard, P.
 TITLE Cloning of cDNA for DARPP-32, a dopamine- and cyclic AMP-regulated neuronal phosphoprotein
 JOURNAL J. Neurosci. 8 (2), 508-517 (1988)
 MEDLINE 88117716
 COMMENT On Dec 16, 1994 this sequence version replaced gi:341699.
 FEATURES
 source Location/Qualifiers
 1..1691
 /organism="Bos taurus"
 /db_xref="taxon:9913"
 /dev_stage="calf"
 /clone="pTKD7"
 /tissue_type="brain (caudate nucleus)"
 gene 342..1680
 /gene="DARPP-32"
 CDS 342..950
 /gene="DARPP-32"
 /note="dopamine and cyclic AMP regulated neuronal protein"
 /codon_start=1
 /product="phosphoprotein"
 /db_xref="PID:g602438"
 /translation="MDPKDRKKIQFSVPAPPSQLDPQVEMIRRRRPTPAMLFRLSEH
 SSPEEEASPHQRASGEGHLLSKRSNFCAYTPPSLKAVQRIAESHLSISNLGENQAS
 EEEDELGLRELGYPREEEEEEEEEDEEEEDSQAELVKGSRGSAGQKTTYGGGLEGP
 WERPPPLDGPQRDGSSEDQVEDPALNEPGEEPQRPAPHEPGT"
 polyA_signal 1675..1680
 /gene="DARPP-32"
 polyA_site 1691
 /gene="DARPP-32"
 BASE COUNT 373 a 530 c 493 g 295 t
 ORIGIN
 1 agcgaaacag agacagaggg agactcgcgg agagggagca agggagatag aggaaggttg
 61 gagagacaca gacagagcga gggaaaggagg gccagagacc agccccgcga gcccaggttg
 121 cggccccagg ggaccgggca cccaggagcc ccagagccgc gagccggccg cccccaccc
 181 ccgcgcgccc tccccgcgc ggcgggtatt tttatctgtg cgtgaacagc cctccagctc
 241 ctctctgcc cactcaaccc gctgccgcg cggcccgag cagcgcgggg gagcggagcg
 301 ggatcgagc ccgagacccc acgacgcgcg cccgcgccgc catggacccc aaagaccga
 361 agaagatcca gttctccgtg cccgcgcccc ccagccagct cgacccccgc cagggtggaga
 421 tgatccggcg caggagacca acccctgcc tgcgttccg gctctcagag cactcctcac
 481 cagaggagga ggcctcacc caccagagag cctcaggaga ggggcaccac ctcaagtcca
 541 agagatccaa tccttgtgcc tacacacccc cctcgctgaa agccgtccag cgcattgctg
 601 agtctcacct gcagtcacat agcaacctgg gtgagaacca ggcctcggag gaggaggatg
 661 agctggggga gctgcgggaa ctgggctacc caagagagga agaggaggag gaagaggagg
 721 aggatgaaga ggaggaggag gacagccagg cggaagtcct gaagggcagc agggggtctg
 781 ctgggcagaa gacaacttat ggccaaggtc tggagggtcc ctgggagcgc ccgcctctc
 841 tggatgggcc ccagagagac ggaagctctg aggaccaagt ggaagacca gcattgaatg

Table 7 (continued)

```

901 aaccgqggga ggagccacag cgccttgccc accctgagcc tggcacatag gcacccagcc
961 ctgcatctcc tggaggaag tgggaggaag cattgatgtt ctccagaaac ccattctgtt
1021 cacaccctat ttgtaccct gcttctcact tgctagggct gcggcttctg acttttagaa
1081 gactaagcct ggctgtgtt tgcttgctg cccaacttcg ctgatcccag agtccctggg
1141 cacttgctgc ctga-gccta cccctgccag tcattccccc atacacccag caggaggtgg
1201 gatgggagag ctgcatctgg gaaatccagt aaatggggga caaagattca tccttcacaa
1261 ttctactccc tagaccctct cccctgggag taggaaacca cagggcagga ccctaagatc
1321 tggggaaaag ggatactgag aacttgtaag tgcccataga tctttctcca tccctgggc
1381 aattccaagt catcacccct tcaactgcct ctaccagggc ccagaattca ggcattcttt
1441 ccacggcctc agcttttggt aaatcttccc cttatcacct gctcccagc ctgggtgcct
1501 ggaagatgga ctggcagaga ctgcttgct gcattttatg tgtgcttga tggcaggaat
1561 gccacctagt ataataagtc cttagggggg cacatggtgg gggagccaag ctctccttgt
1621 cctccagctg ctctgtcccc tccccctct cctgactcc cggcctgaac ctgtaataaa
1681 tctttgtaaa t

```

IV. Routes of Administration, Formulations, and Dosages

In general, the compositions and agents described herein for use in the methodology can be administered in any appropriate carrier for oral, topical, or parenteral administration under in-vivo conditions to a living host subject. The compositions can be introduced by any means that brings access to the vascular endothelial cells within the tissues and organs in the host body. The dosage administered will, of course, vary and be dependent upon the age, health, and weight of the intended recipient; the kind of concurrent treatment, if any; the frequency of treatment, and the degree of the therapeutic effect desired.

If the compositions and agents are to be administered topically, they can be admixed in a concentration range in a pharmaceutically inert topical carrier such as a gel, an ointment, a lotion, or a cream and include such carriers as water, glycerol, alcohol, propylene glycol, fatty alcohols, triglycerides, fatty acid esters, or mineral oils. Other topical carriers are represented by liquid petrolatum, isopropyl palmitate and the like. In addition, minerals such as anti-oxidants, viscosity stabilizers and the like may be added if and when necessary.

If the compositions and agents are to be given parenterally, these compositions will be prepared in sterile form; in multiple or single dose formats; and dispersed in a fluid carrier such as sterile physiological saline, or 5% dextrose solutions commonly used with injectables. In addition, other modes of administration such as perfusion, intravenous injection, and lavage may be advantageously employed as well.

V. Experiments And Empirical Data

To demonstrate the merits and value of the present invention, a series of planned experiments and empirical data are presented below. It will be expressly understood, however, that the experiments described and the results provided are merely the best evidence of the subject matter as a whole which is the invention; and that the empirical data, while limited in content, is only illustrative of the scope of the invention envisioned and claimed.

Experimental Series I

This series of experiments was performed to determine whether the syndecan-4 molecule is itself subject to phosphorylation; and also to determine whether such phosphorylation is affected by the binding of a growth factor (bFGF) to its receptors on the cell surface.

Experimental Procedures:

Materials

Calyculin, chelerythrine, PMA, and bFGF were purchased from Sigma. Gö 6976 was purchased from Calbiochem (La Jolla, CA). Chelerythrine, PMA, and Gö 6976 were dissolved in Me₂SO.

Isolation of Syndecan-4 Core Proteins

NIH 3T3 cells (American Type Culture Collection, Bethesda, MD) were grown to confluence in 100-mm plates in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (Life Technologies Inc.) at 37 °C in a 5% CO₂ humidified atmosphere. The cells were harvested by scraping in 1 ml of lysis buffer (150 mM NaCl, 20 mM NaF, 20 mM Na₄P₂O₇, 5 mM EDTA, 5 mM EGTA, 1 mM Na₃VO₄, 1 mM phenylethylsulfonyl fluoride, 1% Triton X-100, 50 mM HEPES, pH 7.4). The lysate was cleared by centrifugation at 9000 x g for 30 min. and then subjected to DEAE-chromatography as described by Scworak *et al.*, *J. Biol. Chem.* 269: 21204-21214 (1994)]. The eluates were dialyzed twice against 10 mM NH₄HCO₃, 1 mM β-mercaptoethanol and concentrated by evaporation under vacuum. The concentrated samples were resuspended in 50 μl of digestion buffer (50 mM NaCl, 4 mM CaCl₂, 20 mM Tris, pH 7.4) and GAG chains were cleaved off the proteoglycan core proteins by 4 h of incubation in a mixture of 0.06 unit of chondroitinase ABC and 1 unit each of heparinases I, II, and III (Sigma) at 37 °C.

Radiolabeling of Cultured Cells

Confluent NIH 3T3 cells were washed twice in phosphate-free DMEM and incubated for 24 h at 37 °C in a 5% CO₂ humidified atmosphere in phosphate-free DMEM supplemented with 0.5% fetal bovine serum. The cells were washed twice
5 with methionine, phosphate, and serum-free DMEM and incubated for 6 h in the same medium, supplemented with 400 µCi/ml [³⁵S]methionine (New England Nuclear, Boston, MA). At the onset of the last 2 h of incubation, 500 µCi/ml [³²P]orthophosphoric acid (New England Nuclear) was added to the medium.

10 Immunoprecipitation of Cytoplasmic and Ectoplasmic Syndecan-4 Domains

Cells were washed with PBS (137 mM NaCl, 10 mM Na₂HPO₄, 3.6 mM KCl, 1.8 mM KH₂PO₄, pH 7.4), dissociated by 0.05% trypsin, 0.5 mM EDTA (Life Technologies, Inc.) in PBS for 10 min at 22 °C, and sedimented by 2000 x g centrifugation at 4 °C for 5 min. The syndecan-4 ectoplasmic domain was
15 immunoprecipitated from 0.5 ml of medium collected before cell trypsinization or from 0.5 ml of supernatant of the latter centrifugation. The cytoplasmic tail was immunoprecipitated from the pellet after a 30-min extraction at 4 °C in 0.5 ml of lysis buffer supplemented with 100 µM leupeptin, 2 µM pepstatin, and 10 nM okadaic acid (Sigma). Total protein concentrations in each fraction were measured
20 by spectrophotometry at 595 nm (DU 640, Beckman, Fullerton, CA) of an aliquot developed for 10 min in Protein Assay Dye Reagent (Bio-Rad). Bovine serum albumin (Life Technologies Inc.) was used as standard.

The medium, trypsinization supernatant, and extracted pellet fractions were precleared by adding 30 µl of 1:1 (v/v) slurry of protein G plus/protein A-agarose
25 beads (Calbiochem), and 10 µl of nonimmune rabbit serum (Life Technologies Inc.). After a 2-h incubation at 4 °C in rotating tubes, the beads were sedimented by 5 min, 5000 x g centrifugation at 4 °C. The cleared samples were supplemented with 40 µl of 1:1 (v/v) slurry of the above beads and 10 µl of rabbit polyclonal antiserum (syndecan-4 ectoplasmic domain-specific antiserum was added
30 to the medium and trypsinization supernatant samples, and cytoplasmic tail-specific antiserum was added to the extracted pellet fraction) and incubated in rotating tubes for 18 h at 4 °C. The agarose beads were collected by centrifugation as above,

- 41 -

washed three times in heparinase digestion buffer, and resuspended in 40 μ l of digestion buffer, and the GAG chains of the bead-attached ectoplasmic domains from the medium and from the trypsinization-supernatant were cleaved as above. The ectoplasmic and cytoplasmic tails were dissociated from the beads by a 10-min incubation in SDS buffer at 95 °C, and the beads were sedimented by a 5 min, 13,000 x g centrifugation at 4 °C.

Electrophoresis, Transfer, Autoradiography and Immunoblotting

Immunoprecipitated, full-length syndecan-4 core proteins were resuspended in Laemmli sample buffer (2% SDS, 10% glycerol), 0.5% β -mercaptoethanol, 0.004% bromphenol blue, 50 mM Tris-HCl, pH 6.8) resolved by SDS-PAGE on a 10% slab gel, and transferred to a polyvinylidene fluoride (PVDF) membrane (Immobilon-P, Millipore, Bedford, MA) for 12 h at 25 mA in 150 mM glycine, 20 mM Tris-HCl, and 20% methanol. The ectoplasmic and cytoplasmic syndecan-4 domains were resolved on a 15% slab gel and transferred for 90 min at 20 mA in 150 mM glycine, 20 mM Tris-HCl, and 30% methanol to a low porosity PVDF membrane (Immobilon-P⁸⁰, Millipore). Radiolabeled bands detected by exposure to film (XAR, Kodak, Rochester, NY) were excised, and their radioactivity was measured in both the ³²P and ³⁵S spectra by scintillation counting (LS 6000IC, Beckman, Fullerton, CA). In some cases, the same membranes were used for immunoblotting prior to band excision.

After blocking in PBS containing 5% nonfat milk powder for 1 h at 22 °C, the membrane was incubated in the same solution supplemented with 1:3000 (v/v) dilution of either ectoplasmic or cytoplasmic tail-specific antiserum for 2 h, washed with PBS, and incubated for 1 h in 5% milk powder-PBS containing 1:2000 diluted goat anti-rabbit IgG conjugated to peroxidase (Vector Laboratories, Burlingame, CA). The secondary antibody was detected, after no additional PBS wash, by chemiluminescence (Western Blot, Chemiluminescence Reagent Plus, New England Nuclear). Molecular weights were estimated by comparison with the electrophoretic mobility of standards (Kaleidoscope Prestained Standards, Bio-Rad).

- 42 -

Densitometry of digitized images of immunoprobed membranes (ScanJet 4c, Hewlett Packard) was performed using ImageQuant software (Molecular Dynamics, Sunnyvale, CA).

5 Thin-Layer Chromatography

Bands excised from PVDF membranes were hydrolyzed for 75 min in 6N HCl at 110 °C. Solvent was evaporated under vacuum, and the sediment was washed thrice with H₂O. The sediment was resuspended in 5 µl of H₂O after the third evaporation, applied to a thin layer cellulose acetate plate (Sigma-Aldrich),
10 and underwent electrophoresis at 1000 V in 5% acetic acid, 0.5% pyridine, pH 3.0. The radiolabeled phosphoamino acids were detected by phospholuminescence (PhosphorImager, Molecular Dynamics). Phosphorylated, unlabeled Ser, Thr, and Tyr (Sigma) were used as standards and were detected by spraying with ninhydrin.

15

Experiment 1

To determine the presence and extent of phosphorylation of the syndecan-4 cytoplasmic tail, full-length heparan and chondroitin sulfate-carrying core proteins
20 were isolated from serum-starved, ³²P-labeled NIH 3T3 cells. The results are shown by Figs. 1A and 1B respectively.

Fig. 1 generally shows the detection of syndecan-4 core protein basal phosphorylation and identification of serine phosphorylation. Lane 1 of Fig. 1A shows an autoradiograph of fibroblast proteoglycans resolved by 10% SDS-PAGE
25 and transferred to a PVDF membrane; Lane 2 of Fig. 1A shows a Western immunoblast of the same membrane shown in lane 1. In comparison, Fig. 1B shows a phospholuminescence image of the acid-hydrolyzed, TLC-separated syndecan-4 band (*syn-4*) shown in Fig. 1. Phosphoamino acids were identified by comparison with the electrophoretic mobility of nonradiolabeled standards: *P-Ser*,
30 *Ser(P)*; *P-Thr*, *Thr(P)*; *P-Tyr*, *Tyr(P)*.

The results of the autoradiography of NIH 3T3 GAG-lysed core proteins is shown in Fig. 1A (lane 1). To identify the syndecan-4 band, the autoradiographed

- 43 -

membrane was probed with an antiserum specific to the cytoplasmic tail of the syndecan-4 core protein. The immunoblotting highlighted a single band that ran at an approximate molecular mass of 36 kDa (Fig. 1A, lane 2). A similar syndecan-4 electrophoretic mobility lower than its predicted molecular mass of 20 kDa was observed before with the same antiserum. As illustrated in Fig. 1A, the antiserum-detected band superimposed precisely on the second band from the bottom in the autoradiograph.

Phosphoamino acid analysis of the syndecan-4 band produced a single, intensely labeled spot that corresponded to the electrophoretic mobility of phosphorylated serine as shown by Fig. 1B. The syndecan-4 core protein sequence contains multiple serines [16 in the human syndecan-4 and 15 in the rat] - all but one of which are located in the ectoplasmic domain.

Experiment 2:

To determine which domain contains the phosphorylated serine, the susceptibility of the ectoplasmic domain of the syndecans to trypsinization was exploited. Thus the core protein of syndecan-4 was cleaved at the cell surface concurrently with the trypsin dissociation of the ^{32}P -labeled, adherent cells from the culture plates. The results are visually seen in Fig. 2.

Fig. 2 shows the localization of syndecan-4 core protein phosphorylation to the cytoplasmic tail. Lane 1 of Fig. 2A shows an autoradiograph of Triton X-100 soluble cell fraction immunoprecipitated with syndecan-4 (*syn-4*) cytoplasmic tail-specific antiserum. Lane 2 of Fig. 2A shows a Western immunoblot of the same membrane shown in lane 1, using syndecan-4 cytoplasmic tail-specific antiserum. Lane 1 Fig. 2B shows Triton X-100 soluble cell fraction immunoprecipitated with syndecan-4 cytoplasmic tail-specific antiserum. Lane 2 of Fig. 2B shows the trypsinized ectoplasmic proteins fraction immunoprecipitated with antiserum specific to the syndecan-4 ectoplasmic domain. Lane 3 of Fig. 2B shows the cell culture medium immunoprecipitated and processed as the sample in lane 2. Autoradiography exposure times were identical for the three samples.

Accordingly, by analogy with syndecan-1, the trypsinization site is most likely between Arg¹⁴⁷ and Thr¹⁴⁸ preceding the transmembrane domain. Following trypsinization and detergent extraction, the cleaved syndecan-4 fragment was isolated by immunoprecipitation with the cytoplasmic tail-specific antiserum, which
5 recognizes a 14-residue cytoplasmic sequence. As with the full-length core protein, the ³²P-labeled immunoprecipitate was separated by SDS-PAGE and transferred to a membrane. The band routinely detected in the autoradiographs of these membranes migrated at an approximate molecular mass of 5 kDa, slightly less than the predicted 7-kDa size of the fragment encompassing the trypsinized
10 transmembrane and cytoplasmic tails (Fig. 2A). This lower apparent molecular mass may have resulted from partial degradation during the isolation process or may reflect a higher electrophoretic mobility than the molecular mass standard used for estimating the band size.

To verify the identity of this band, the same membrane was reprobed with
15 the antiserum that recognizes the cytoplasmic tail. The immunoblotted band overlapped the ³²P-labeled one (Fig. 2A), confirming that the latter is comprised of the Ser¹⁸³-phosphorylated cytoplasmic tail of syndecan-4.

To rule out phosphorylation of additional serines in the syndecan-4 core protein outside the cytoplasmic tail, the phosphorylation was examined in three
20 different fractions: (a) the medium, which could contain shed ectoplasmic syndecan-4; (b) the supernatant of the sedimented trypsinized cells, containing the cleaved ectoplasmic domain; and (c) the detergent-soluble fraction extracted from the pellet of the sedimentation, containing the transmembrane and cytoplasmic domains. The ectoplasmic domain of syndecan-4 was immunoprecipitated from the
25 first two fractions with an antiserum specific to this domain; and the third fraction was immunoprecipitated with the cytoplasmic tail-specific antiserum. Auto-radiography of the SDS-PAGE-separated fractions revealed a single band in the cytoplasmic fraction lane. No radioactive bands were detected in the lanes of the other two fractions (Fig. 2B). This clearly localizes the phosphorylation to the
30 single serine residue in the cytoplasmic tail of the core protein of syndecan-4.

- 45 -

Experiment 3:

To determine the stoichiometry of the basal phosphorylation of syndecan-4, as well as the effect of bFGF and of other compounds on this phosphorylation, the cells were doubly labeled with [³⁵S]methionine and [³²P]orthophosphoric acid. The syndecan-4 carboxyl-terminal proteolytic fragment produced by trypsinization between Arg¹⁴⁷ and Thr¹⁴⁸ (referring to the rat sequence numbering) contains a single methionine (Met¹⁷⁶). Because we have shown above that the phosphorylation of syndecan-4 occurs at a single Ser¹⁸³, the molar ratio of ³²P/³⁵S, as calculated from their specific activities, should be equivalent to the ratio of mol P_i/mol syndecan-4, assuming the two radio probes have similar incorporation efficiencies. Because this quantitation method is radiometric, the result is independent of the absolute amounts of protein processed. Using this approach, the stoichiometry of the basal phosphorylation of syndecan-4 in cells starved for 24 h in 0.5% serum, followed by 6 h of serum-free starvation, was 0.31 ± 0.12 (mean \pm S.D., $n = 5$) of mol P_i/mol syndecan-4.

Experiment 4:

The participation of the syndecan ectoplasmic domain in bFGF binding raises the question whether this binding is accompanied by intracellular modifications of syndecan-4, such as phosphorylation of its cytoplasmic tail. The results of Fig. 3 reveal the true answer.

Fig. 3 shows the effects of bFGF and calyculin on syndecan-4 cytoplasmic tail phosphorylation. Fig. 3A shows the cumulative results of the effects of bFGF ($n = 4$), calyculin (*cal*, $n = 3$), and bFGF together with calyculin (*bFGF+cal*, $n = 3$) on syndecan-4 cytoplasmic tail phosphorylation, relative to untreated control cells (cont). Bars denote standard deviation. The inset shows autoradiographs of cell lysates immunoprecipitated with syndecan-4 cytoplasmic tail-specific antiserum. Lane 1 represents bFGF-untreated cells. Lane 2 represents cells treated with 10 ng/ml bFGF. Lane 3 represents cells treated concurrently with 10 ng/ml bFGF and 5 nM calyculin. Arrow denotes the syndecan-4 band.

Fig. 3B reveals the dependence of syndecan-4 cytoplasmic tail phosphorylation on bFGF concentration. Phosphorylation stoichiometry was calculated as the ratio of $^{32}\text{P}/^{35}\text{S}$ counts of the syndecan-4 bands excised from PVDF membranes. Inset shows immunoblotted syndecan-4 bands from control and bFGF-treated (10 ng/ml) cells. Cell lysates containing equal amounts of total protein were applied in each lane.

Experimentally, treatment with 10 ng/ml of bFGF during the last 5 h of the serum-free starvation decreased the phosphorylation stoichiometry of syndecan-4 to 0.16 ± 0.02 ($n = 5$), approximately half its basal level (Fig. 3A). Larger bFGF dosages of 20 and 30 ng/ml further decreased the phosphorylation stoichiometry of syndecan-4 to 0.12 ± 0.06 ($n = 3$), but this decrease was not statistically different from the effect of 10 ng/ml bFGF (Fig. 3B).

To test for the possible involvement of a phosphatase in the bFGF-induced decrease of syndecan-4 phosphorylation, phosphatase 1/2A inhibitor calyculin (5 nM) was applied to bFGF (10 ng/ml)-treated cells. Calyculin countered the effect of bFGF, maintaining the syndecan-4 phosphorylation at its basal level (Fig. 3B). Moreover, when the same calyculin dose was applied to cells in the absence of bFGF, syndecan-4 phosphorylation was increased more than 2.5-fold relative to the basal level.

If, contrary to our assumption, the incorporation efficiency of ^{35}S is higher than that of ^{32}P , the bFGF-induced decrease in syndecan-4 phosphorylation could solely result from bFGF up-regulation of syndecan-4 synthesis. To address this possibility, the syndecan-4 expression levels in control and in bFGF-treated cells (processed identically to those in the phosphorylation assays) were compared by immunoblotting cell lysates containing equal amounts of total protein. The syndecan-4 bands, which similar to immunoprecipitated samples (Fig. 2A) ran at an approximate molecular mass of 5 kDa, were detected with the antiserum specific to the ectoplasmic domain; and the amount of protein in each band was quantified by densitometry. In cells treated by 10 and by 30 ng/ml bFGF, the level of syndecan-4 expression was 85% (Fig. 3B, inset) and 93% of the control cells, respectively.

Experiment 5:

The possible involvement of PKC in syndecan-4 phosphorylation was then investigated. The experiment data is provided by Fig. 4.

5 Fig. 4 reveals the effects of PKC activation and inhibition on syndecan-4 cytoplasmic tail phosphorylation. Fig. 4A shows a phospholuminescence image of acid-hydrolyzed, TLC-separated, syndecan-4 (*syn-4*) bands excised from PVDF membranes of control cells treated by Me₂-SO alone (Lane 1) and from cells treated with 0.5 μ M PMA (lane 2). Fig. 4B shows autoradiographs of
10 immunoprecipitates from control (lane 1) and PMA-treated cells (lane 2) resolved by SDS-PAGE and transferred to a PVDF membrane. Fig. 4C shows the dependence of syndecan-4 phosphorylation stoichiometry on chelerythrine concentration. Chelerythrine was applied to the cells together with 0.5 μ M PMA. These results are representative of two experiments.

15 Procedurally, to up-regulate PKC, cells were treated with the PKC-activating phorbol ester PMA (0.5 μ M) during the last 5 h of the serum-free starvation. This treatment increased only the Ser¹⁸³ phosphorylation of syndecan-4, without having a detectable effect on the phosphorylation of threonine or tryptine residues in the cytoplasmic tail (Fig. 4A). The stoichiometry of the
20 phosphorylation of syndecan-4 in the PMA-treated cells was 0.81 ± 0.33 ($n = 3$), close to 3-fold higher than the basal level. This result indicates that syndecan-4 is either a direct or an indirect PKC substrate.

To further examine the role of PKC in syndecan-4 phosphorylation, the PKC-specific inhibitor chelerythrine was applied to PMA-stimulated cells. The
25 phosphorylation of syndecan-4 started to decline at chelerythrine concentrations above 1.5 μ M and was reduced to an undetectable level at 6 μ M chelerythrine (Fig. 4, B and C). The latter concentration is less than 10% of the IC₅₀ of chelerythrine for the inhibition of protein tryosine kinases. Although supporting the role of PKC in the phosphorylation of syndecan-4, these results do not identify
30 the specific isozyme involved, because both PMA and chelerythrine affect all the four known calcium-dependent cPKCs, as well as the five calcium-independent nPKCs.

To further narrow down the group of possible PKC isozymes, the indolocarbazole Gö 6976, which inhibits calcium-dependent PKC isozymes, was applied to PMA (0.5 μ M)-treated cells. The phosphorylation of syndecan-4 was not reduced, however, by Gö 6976 concentrations up to 100 nM, more than 10-fold its IC₅₀ for cPKC (data not shown). It is likely, therefore, that the syndecan-4 cytoplasmic tail is phosphorylated by one of the nPKC isozymes.

Conclusions:

1. The cytoplasmic tail of syndecan-4 is phosphorylated in cultured fibroblasts and that the extent of its phosphorylation is determined by activities of a nPKC enzyme and a bFGF-activated phosphatase. The phosphorylation site was localized to Ser¹⁵³, immediately upstream of a nine-amino acid segment involved in binding to and activation of PKC α .
2. The experimental series showed a relatively high degree of syndecan-4 phosphorylation in growth-arrested cells, which could be further increased by treatment with PMA or decreased by bFGF. Because Ser¹⁸³ is part of an invariant seven-residue sequence (KKDEGSY), these findings may be relevant to all four members of the syndecan family.
3. The PMA-induced increase in the phosphorylation of syndecan-4 and its decrease by chelerythrine strongly suggest the involvement of PKC in this phosphorylation. In agreement with this observation, we were unable to suppress the PMA-induced phosphorylation of syndecan-4 by a cPKC-specific inhibitor, pointing to the participation of a nPKC isozyme in the phosphorylation.
4. A phosphatase inhibitor reversed the bFGF-induced reduction in syndecan-4 phosphorylation observed in our study. This suggests that bFGF binding up-regulates a phosphatase and/or down-regulates a kinase involved in controlling the level of Ser¹⁸³ phosphorylation.

Experimental Series II

These experiments are directed to investigating the effect of phosphorylation of the cytoplasmic tail of syndecan-4 upon its interaction with phosphatidylinositol 4,5-biphosphate (hereinafter "PIP₂") which binds directly to the cytoplasmic tail of syndecan-4 and facilitates its multimerization; as well as its capacity to activate Protein Kinase C α . The involvement of PIP₂ for binding and multimerization has been reported previously in the scientific literature [Oh *et al.*, *J. Biol. Chem.* 272: 11805-11811 (1997); Oh *et al.*, *J. Biol. Chem.* 273: 10624-10629 (1998); and Lee *et al.*, *J. Biol. Chem.* 273: 13022-13029 (1998)]. However, the functional effects of phosphorylating the cytoplasmic region of the syndecan-4 and its effects on the molecular properties and signaling activity have not yet been elucidated.

Experimental Procedures:

Materials

Phosphatidylinositol 4,5-biphosphate (PIP₂), phosphatidylserine (PS), and diolein were purchased from Sigma. Recombinant PKC α and PKC δ were synthesized and prepared as described in Nishikawa *et al.*, *J. Biol. Chem.* 272: 952-960 (1997). PKC β 1 optimal substrate peptide (FKLKRKGSFKKFA) was purchased from Tufts University Medical School (Boston, MA). A 28 amino acid-long syndecan-4 cytoplasmic tail peptide (S4c) (RMKKKDEGSYDLG KKPIYKKAPTNEFYA) was synthesized by Genemed Synthesis (South San Francisco, CA). A similar peptide with a phosphorylated Ser (S4c-P) was synthesized by the Biopolymers Laboratory, Harvard Medical School (Boston, MA).

PIP₂ Binding Assay

PIP₂ (from Sigma, dissolved at 2 mg/ml in 20 parts CHCl₃, 9 parts MeOH, 1 part H₂O, 0.1 part 1N HCl) was dried under N₂ and sonicated for 5 min in ice-cold H₂O at a final concentration of 1 mg/ml. Syndecan-4 cytoplasmic tail peptides S4c or S4c-P (100 μ M) were incubated on ice for 30 min with the indicated concentrations of PIP₂ in 10 mM Tris-HCl (pH 7.5), 75 mM KCl,

- 50 -

0.5 mM DTT, in aliquots of 100 μ l. The samples were layered on 30 kDA-molecular-mass cutoff cellulose filters (Ultrafree-MC, Millipore, Bedford, MA), and spun at 2000 g for 1 min, following the method described in Haarer *et al.*, *Mol. Cell Biol.* 13: 7864-7873 (1993). The samples (40 μ l of each in Laemmli sample buffer, 2% SDS, 10% glycerol, 0.5% β -mercaptoethanol, 0.004% bromophenol blue, 50 mM Tris-HCl, pH 6.8) were resolved by SDS-PAGE on 16.5% Tris-tricine gels (BioRad Laboratories, Hercules, CA). Gels were stained with Coomassie Brilliant Blue G-250 (BioRad Laboratories), and images of the stained bands were digitized (DeskScan II on ScanJet 4c, Hewlett Packard) and quantitated by densitometry (ImageQuant, Molecular Dynamics, Sunnyvale, CA).

Size-exclusion Chromatography

Syndecan-4 cytoplasmic tail peptides S4c or S4c-P (300 μ M) were incubated with PIP₂ (350 μ M, prepared as above) in 0.5 ml mM HEPES (pH 7.3), 150 mM NaCl, on ice for 30 min. Samples were applied at 4 °C to a Sephadex G-50 (Pharmacia Biotech, Uppsala, Sweden) 30 x 1.6 cm column equilibrated with the incubation buffer, and the absorbency of the flow through was measured at 280 nm.

Immunoprecipitation

Rat fat pad capillary endothelial cells (RFPEC, gift of Dr. R.D. Rosenberg, MIT (11) were grown to confluence in M199 medium supplemented with 10% FBS (Life Technologies) at 37 °C in a 5% CO₂ humidified atmosphere. The cells were harvested by trypsinization, lyzed, and subjected to immunoprecipitation with a cytoplasmic tail-specific antiserum as described previously in Experimental Series I.

Electrophoresis, Transfer, and Immunoblotting

Immunoprecipitated syndecan-4 cytoplasmic tail was re-suspended in Laemmli sample buffer and resolved by SDS-PAGE on a 4-20% Tris-glycine gel (BioRad), and transferred for 2 hrs at 250 mA in 150 mM glycine, 20 mM Tris-

- 51 -

HCl, and 20% methanol to a polyvinylidene fluoride (PVDF) membrane (Immobilon-P, Millipore). The membranes were immunoblotted as described previously in Experimental Series I using polyclonal antibodies to PKC α or to PKC δ (both at 2 μ g/ml; purchased from Santa Cruz Biotechnology, Santa Cruz, CA).

Syndecan-4 Cytoplasmic Tail Peptide - PKC Binding Assay

Cytoplasmic tail peptides S4c or S4c-P (10 μ M) were incubated on ice for 30 min either in the presence or absence of PIP₂ (20 μ M; prepared as above) with recombinant PKC α (4 μ M) in 0.5 ml of the same buffer used in the PIP₂ binding assay. The cytoplasmic tail peptide was immunoprecipitated, and the samples were resolved by SDS-PAGE, transferred, and immunoblotted as described above.

PKC In Vitro Assays

Samples (30 μ l) consisted of PKC β 1 optimal substrate peptide (100 μ M) either with or without syndecan-4 cytoplasmic tail peptides S4c or S4c-P (both at 50 μ M) in 25 mM Tris-HCl (pH 7.4), 5 mM MgCl₂, 1 mM DTT, 50 μ M ATP, and 5 μ Ci [γ -³²P]ATP (New England Nuclear, Boston, MA). In some assays the buffer was supplemented with either PIP₂ (50 μ M), or PS (4 μ g/ml), diolein (6.2 μ g/ml), and 0.2 mM CaCl₂. In PKC δ assays the buffer was supplemented with PS and diolein as above, and with 0.5 mM EGTA. Upon addition of either PKC α (120 ng/ml) or PKC δ (430 ng/ml), samples were incubated at 30 °C for 10 min, and reactions were stopped by boiling in Laemmli sample buffer for 4 min. The samples were resolved on 16.5% Tris-tricine gels (BioRad Laboratories), transferred to PVDF membranes and detected as described previously in Experimental Series I.

Experiment 6:

Syndecan-4 cytoplasmic tail has been shown to activate a mixture of Ca²⁺-dependent PKCs and of recombinant PKC α in the presence of PIP₂. To assess the effect of Ser¹⁸³ phosphorylation on syndecan-4-dependent PKC activation, the

ability of the 28 amino acid-long syndecan-4 cytoplasmic tail peptide, S4c, and S4c-P peptides to activate recombinant PKC α was studied using the PKC β 1 optimal substrate peptide in an in-vitro assay. The results are graphically illustrated by Fig. 5.

- 5 Fig. 5 shows the activation of PKC α cytoplasmic tail peptides. Densitometry histograms of autoradiographic images of PKC β 1 optimal substrate peptide were resolved on 16.5% Tris-tricine gels and then transferred to PVDF membranes ($n=3$; bars denote SD). The substrate was phosphorylated in-vitro by recombinant PKC α (120 ng/ml) in the presence of PS (4 μ l/ml), diolein
10 (6.2 μ g/ml), and 0.2 mM calcium (white bars), initially without co-factors (striped bars), and then in the presence of 50 μ M PIP $_2$ (black bars). Assays were performed under each set of conditions in the absence (Cont), and in the presence of 50 μ M non-phosphorylated (S4c), or phosphorylated (S4c-P) syndecan-4 cytoplasmic tail peptides. The inset shows autoradiographic images of PKC β 1
15 optimal substrate peptide phosphorylated in the presence of 50 μ M PIP $_2$.

- When the assays were carried out with the standard cPKC cofactors PS, DAG and calcium, the presence of neither the S4c, nor the S4c-P peptides had any additional effect on the catalytic activity of PKC α , as shown by Fig. 5. The same result was observed in PKC assays where no cofactors were added. However, the
20 assay conducted in the presence of PIP $_2$, together with the S4c peptide, revealed that the catalytic activity of PKC α towards the PKC β 1 peptide was approximately 10-fold larger than in assays with PIP $_2$ alone. On the other hand, when the S4c-P peptide was added instead of S4c, the phosphorylation level of the substrate was similar to that obtained with PIP $_2$ alone. Unlike PKC α , the S4c peptide did not
25 activate PKC δ under the same conditions (data not shown). The activity of PKC α in the presence of the S4c peptide and PIP $_2$ was $72 \pm 10\%$ (\pm SD, $n = 3$) of its activity in the presence of the S4c peptide, PS, DAG, and calcium.

Experiment 7:

The ability of the unphosphorylated but not the phosphorylated cytoplasmic tail of syndecan-4 to activate PKC α in-vitro may relate to a reduced PKC α affinity upon phosphorylation of the cytoplasmic tail. Previous studies [Oh *et al.*, *J. Biol. Chem.* **272**: 8133-8136 (1997)] have demonstrated the ability of the cytoplasmic tail of syndecan-4 to bind PKC; and narrowed the identity of the bound PKC isozyme in-vivo down to a group of four (α , β I, β II, γ , and δ). Though PKC α was shown to bind to the cytoplasmic tail of syndecan-4 in-vitro, the cytoplasmic tail could also bind to and be a substrate of PKC δ . To determine the ability of syndecan-4 to bind PKC α or δ in-vivo, RFPEC lysates were immunoprecipitated with an antiserum specific to the cytoplasmic tail, and the immunoprecipitants were probed with antibodies specific either to the α or δ PKC isozymes. The results are shown by Figs. 6A-6C respectively.

Fig. 6 reveals the PKC binding to syndecan-4 cytoplasmic tail peptides. Fig. 6A shows immunoblots of recombinant PKC α (lane 1), and of syndecan-4 cytoplasmic tail immunoprecipitated from RFPEC lysate (lane 2). Samples were resolved on 4-20% Tris-glycine gels, transferred to PVDF membranes, and probed with a polyclonal antibody to PKC α . Fig. 6B is similar to Fig. 6A but lane 1 is an immunoblot of recombinant PKC δ , and the membrane was probed with a polyclonal antibody to PKC δ . Fig. 6C shows an immunoblot of recombinant PKC α (4 μ M) incubated with 10 μ M non-phosphorylated (lanes 1,2), or phosphorylated (lanes 3,4) syndecan-4 cytoplasmic tail peptides in the absence (lanes 1,3) or in the presence (lanes 2,4) of 20 μ M PIP $_2$, and immunoprecipitated with antiserum specific to the cytoplasmic tail of syndecan-4.

As shown by Figs. 6A and 6B respectively, the presence of PKC α but not of PKC δ was detected in the immunoprecipitants. The results clearly evidence these facts.

To analyze the effects of syndecan-4 cytoplasmic tail phosphorylation on its ability to bind PKC α , in-vitro assays with recombinant PKC α and the S4c and S4c-P peptides were then performed. Incubation of PKC α with either peptide produced, however, similar degrees of binding both in the presence and absence of

PIP₂ (Fig. 6C). It follows, therefore, that PKC α binding is not affected by Ser¹⁸³ phosphorylation in the syndecan-4 cytoplasmic tail and thus cannot explain the effect of syndecan-4 phosphorylation on the enzyme's activity.

5

Experiment 8:

Both the oligomerization and PKC α activation capacities of the cytoplasmic tail of syndecan-4 have been reported as depending on the presence of PIP₂ [Oh et al., J. Biol. Chem. **272**: 11805-11811 (1997); Lee et al., J. Biol. Chem. **273**: 13022-13029 (1998)]. It was of interest, therefore, to determine whether the phosphorylation of Ser¹⁸³ in the cytoplasmic tail of syndecan-4 affects the affinity of the tail to PIP₂. To this end, the in-vitro binding between PIP₂ micelles and S4c or S4c-P peptides was compared using a filtration assay. The filter retains the PIP₂ micelle-bound peptide, while the unbound peptide passes through it. The results are illustrated by Figs. 7A and 7B respectively.

Fig. 7 shows the binding between PIP₂ and syndecan-4 cytoplasmic tail peptides. Fig. 7A shows the filter flow-through samples of non-phosphorylated (S4c) and phosphorylated (S4c-P) syndecan-4 cytoplasmic tail peptides, after incubation with PIP₂ at the indicated concentrations. Samples were resolved on 16.5% Tris-tricine gels. Fig. 7B graphically illustrates the densitometry results of the gel bands of the S4c (black bars) and S4c-P (white bars) peptides shown in Fig. 7A.

Fig. 7 demonstrates that the binding affinity of the S4c peptide to PIP₂, as determined by band densitometry of the SDS-PAGE-resolved filter flow-through samples, was significantly higher than that of the S4c-P peptide. At a peptide:PIP₂ molar ratio of 2:1, 50% of the S4c peptide that passed through the filter in the absence of PIP₂ was retained, versus none of the S4c-P peptide. Practically all the applied S4c peptide was retained by the filter at a peptide:PIP₂ molar ratio of 1:2, while as much as 50% of the S4c-P peptide still passed through the filter under the same conditions. The dissociation constants (K_d) calculated from the results shown

30

- 55 -

in Fig. 7 were $2.4 \mu\text{M}$ for the non-phosphorylated peptide (S4c), vs. $232 \mu\text{M}$ for the phosphorylated one (S4c-P). Thus, Ser¹⁸³ phosphorylation results in significant reduction in the ability of PIP₂ to bind to the cytoplasmic tail of syndecan-4.

5

Experiment 9:

Previous studies have demonstrated that the cytoplasmic tail of syndecan-4 undergoes oligomerization in the presence of PIP₂; furthermore this oligomerization appeared necessary for PKC α activation. The reduced affinity between the
10 cytoplasmic tail and PIP₂ caused by phosphorylation could conceivably be accomplished by changes in the oligomerization properties of syndecan-4. To compare the oligomerization of the S4c peptide to that of the phosphorylated peptide S4c-P, both were incubated either in the presence or absence of PIP₂, as described in the Experimental Procedures, and passed through a size exclusion
15 column. The results are graphically represented by Fig. 8A-8D respectively.

Fig. 8 shows the size-exclusion column chromatography of syndecan-4 cytoplasmic tail peptides. Figs. 8A and 8C present absorbency profiles at 280 nm of flow-through samples of non-phosphorylated samples; and Figs. 8B and 8D present phosphorylated syndecan-4 cytoplasmic tail peptides. The samples of
20 Figs. 8A and 8B were incubated without PIP₂; while the samples of Figs. 8C and 8D contained PIP₂. The results shown in Figs. 8C and 8D are representative of two experiments.

As Figs 8A and 8B reveal, both peptides eluted as a single peak when incubated in the absence of PIP₂. When the mixtures are incubated in the presence
25 of PIP₂, however, the S4c peptide eluted as two peaks - one of an approximate molecular mass of 7 kDa (Fig. 8C), and another heavier peak of a molecular mass greater than 17 kDa (the molecular mass of the heaviest molecular mass standard used in this experiment). The S4c-P peptide, on the other hand, eluted as a single peak of the same approximate molecular mass as the first peak of the S4c peptide
30 (Fig. 8D). These results indicate the cytoplasmic tail of syndecan-4 loses its capacity to form oligomers upon phosphorylation of Ser¹⁸³. Based on the position of the first peaks of the S4c and the S4c-P peptides, it appears that both the S4c

and the S4c-P peptides formed dimers, similar to the behavior observed in the PIP₂-binding experiment (see Fig. 7). The broader peaks observed with both peptides when incubated in the presence of PIP₂, compared with the sharper ones obtained in the absence of PIP₂, reflect a wider spread in molecular weight, probably resulting from the range of PIP₂ binding to the peptides.

Conclusions:

1. This experiment series presents three distinct findings concerning the role of the syndecan-4 core protein in signal transduction: (a) phosphorylation of a single serine residue (Ser¹⁸³) located in the membrane-proximal part of the cytoplasmic tail of syndecan-4 reduces the affinity of the tail to the phosphoinositide PIP₂. Upon phosphorylation, the cytoplasmic tail loses its capacity to (b) undergo multimerization and to (c) activate PKC α in the presence of PIP₂. These findings provide the first evidence for a functional role of the phosphorylation of Ser¹⁸³ in the cytoplasmic tail of syndecan-4.
2. The capacities of the cytoplasmic tail of syndecan-4 to undergo multimerization and to activate PKC α were manifest only in the presence of PIP₂. The mechanism of PKC α activation by the cytoplasmic tail of syndecan-4 requires formation of cytoplasmic tail multimers. Ser¹⁸³ phosphorylation prevents this oligomerization by inhibiting PIP₂ binding to the variable region of the syndecan-4 cytoplasmic tail. It follows, therefore, that the loss of PKC α activation by the cytoplasmic tail upon phosphorylation of Ser¹⁸³ is a direct consequence of the concomitant reduction in affinity to PIP₂ and impaired multimerization. Since the cytoplasmic tail of syndecan-4 did not activate PKC δ , this activation may be specific to PKC α . On the other hand, Ser¹⁸³ phosphorylation had no effect on the capacity of the syndecan-4 cytoplasmic tail to bind PKC α . The ability of syndecan-4 to activate PKC α signaling in endothelial cells, the regulation of this signaling by syndecan-4 phosphorylation, and the previously demonstrated bFGF-dependent regulation of the state of syndecan-4 cytoplasmic tail phosphorylation reveals the existence of a novel bFGF-dependent signaling pathway.

- 57 -

The present invention is not restricted in form nor limited in scope except by the claims appended hereto.

What we claim is:

1. A method for stimulating angiogenesis within variable cells, tissues, and organs in-situ, said method comprising:
 - 5 identifying a viable endothelial cell in-situ as a target, said targeted endothelial cell bearing a plurality of transmembrane syndecan-4 proteoglycans positioned at and through the cell surface wherein the 183rd amino acid residue present within the intracellular cytoplasmic domain of said syndecan-4 proteoglycan is a serine residue;
 - 10 administering to said targeted endothelial cell on at least one occasion a predetermined amount of an inhibitor of Protein Kinase C δ (delta) isoenzyme activity such that said 183rd serine residue within the cytoplasmic domain of at least some of said syndecan-4 proteoglycans is present in a non-phosphorylated state; and
 - 15 allowing said 183rd serine residue within the cytoplasmic domain of said syndecan-4 proteoglycans to continue to be present in a non-phosphorylated state, whereby a stimulation of angiogenesis in-situ results.
2. A method for stimulating angiogenesis within viable cells, tissues, and organs in-situ, said alternative method comprising:
 - 20 identifying a viable endothelial cell in-situ as a target, said targeted endothelial cell bearing a plurality of transmembrane syndecan-4 proteoglycans positioned at and through the cell surface wherein the 183rd amino acid residue present within the intracellular cytoplasmic domain of said syndecan-4 proteoglycan
 - 25 is a serine residue;
 - administering to said targeted endothelial cell on at least one occasion a predetermined amount of a composition able to increase Protein Kinase C α (alpha) isoenzyme activity intracellularly such that said 183rd serine residue within the cytoplasmic domain of at least some of said syndecan-4 proteoglycans is present in
 - 30 an non-phosphorylated state in-situ; and

- 59 -

allowing said 183rd serine residue within the cytoplasmic domain of said syndecan-4 proteoglycans to continue to be present in a non-phosphorylated state, whereby a stimulation of angiogenesis in-situ results.

- 5 3. A method for stimulating angiogenesis within viable cells, tissues, and organs in-situ, said alternative method comprising:

identifying a viable endothelial cell in-situ as a target, said targeted endothelial cell bearing a plurality of transmembrane syndecan-4 proteoglycans positioned at and through the cell surface wherein the 183rd amino acid residue
10 present within the intracellular cytoplasmic domain of said syndecan-4 proteoglycan is a serine residue;

administering to said targeted endothelial cell on at least one occasion a predetermined amount of a substance able to activate at least one enzyme selected from the group consisting of protein phosphatases 1 and 2A such that said 183rd
15 serine residue within the cytoplasmic domain of at least some of said syndecan-4 proteoglycans is present in a non-phosphorylated state; and

allowing said 183rd serine residue within the cytoplasmic domain of said syndecan-4 proteoglycans to continue to be present in a non-phosphorylated state, whereby a stimulation of angiogenesis in-situ results.

20

4. The method as recited in claim 1 wherein said inhibitor of Protein Kinase C δ (delta) isoenzyme activity is selected from the group consisting of chemical PKC inhibitors, over-expressed DNA encoding the pseudosubstrate domain of PKC δ (delta) isoenzyme, and prepared anti-sense PKC δ (delta) oligonucleotide
25 sequences.

5. The method as recited in claim 2 wherein said composition able to increase Protein Kinase C α (alpha) isoenzyme activity is selected from the group consisting of phorbol esters, over-expressed DNA encoding the PKC α (alpha) isoenzyme
30 molecule, and over-expressed DNA encoding the PKC α (alpha) catalytic domain.

6. The method as recited in claim 3 wherein said activating substance is selected from the group consisting of over-expressed DNA encoding the catalytic subunits of the protein phosphatase and over-expressed DNA encoding the regulatory units of the protein phosphatase.

1/8

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7





Fig. 8



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/26647

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : Please See Extra Sheet.

US CL : 435/455; 514/2, 44; 536/23.5, 24.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/455; 514/2, 44; 536/23.5, 24.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GALLO et al. Syndecans, cell surface heparan sulfate proteoglycans, are induced by a proline-rich antimicrobial peptide from wounds. Proc. Natl. Acad. Sci. USA. November 1994. Vol. 91, pages 11035-11039, entire document.	1-6
A	KOJIMA et al. Molecular cloning and expression of two distinct cDNA-encoding heparan sulfate proteoglycan core proteins from a rat endothelial cell line. J. Biol. Chem. 05 March 1992. Vol. 267, No. 7, pages 4870-4877, entire document.	1-6

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

24 FEBRUARY 2000

Date of mailing of the international search report

05 APR 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ANNE-MARIE BAKER, Ph.D.

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/26647

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	LEE et al. Solution structure of a syndecan-4 cytoplasmic domain and its interaction with phosphatidylinositol 4,5-bisphosphate. J. Biol. Chem. 22 May 1998. Vol. 273, No. 21, pages 13022-13029, entire document.	1-6
A	NISHIKAWA et al. Determination of the specific substrate sequence motifs of protein kinase C isoenzymes. J. Biol. Chem. 10 January 1997. Vol. 272, No. 2, pages 952-960, entire document.	1-6
A	OH et al. Multimerization of the cytoplasmic domain of syndecan-4 is required for its ability to activate protein kinase C. J. Biol. Chem. 02 May 1997. Vol. 272, No. 18, pages 11805-11811, entire document.	1-6
A	OH et al. Syndecan-4 proteoglycan regulates the distribution and activity of protein kinase C. J. Biol. Chem. 28 March 1997. Vol. 272, No. 13, pages 8133-8136, entire document.	1-6

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/26647

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (7):

A61K 38/00, 48/00; C07H 21/04; C12N 15/63

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

WEST (all databases)

Dialog (file: medicine)

search terms: m. simons, a. horowitz, syndecan 4, phosphorylat?, angiogenesis, serine, protein kinase C, PKC, protein phosphatase I, protein phosphatase 2A, inhibit?

THIS PAGE BLANK (USPTO)